WO2009042802A1 - Edible and biocompatible metal-organic frameworks - Google Patents
Edible and biocompatible metal-organic frameworks Download PDFInfo
- Publication number
- WO2009042802A1 WO2009042802A1 PCT/US2008/077741 US2008077741W WO2009042802A1 WO 2009042802 A1 WO2009042802 A1 WO 2009042802A1 US 2008077741 W US2008077741 W US 2008077741W WO 2009042802 A1 WO2009042802 A1 WO 2009042802A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- metal
- bmof
- framework
- group
- Prior art date
Links
- 239000012621 metal-organic framework Substances 0.000 title claims abstract description 54
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 39
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 39
- 239000000463 material Substances 0.000 claims abstract description 31
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 15
- 239000003124 biologic agent Substances 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 6
- 229910052751 metal Inorganic materials 0.000 claims description 82
- 239000002184 metal Substances 0.000 claims description 82
- 239000003446 ligand Substances 0.000 claims description 63
- -1 wherein Rl can be -H Chemical group 0.000 claims description 39
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 239000013354 porous framework Substances 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 19
- 239000011148 porous material Substances 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 239000007789 gas Substances 0.000 claims description 15
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 14
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 14
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 14
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 14
- 239000001301 oxygen Substances 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 239000013626 chemical specie Substances 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 11
- 125000004429 atom Chemical group 0.000 claims description 11
- QMKYBPDZANOJGF-UHFFFAOYSA-N benzene-1,3,5-tricarboxylic acid Chemical compound OC(=O)C1=CC(C(O)=O)=CC(C(O)=O)=C1 QMKYBPDZANOJGF-UHFFFAOYSA-N 0.000 claims description 11
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 10
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 claims description 10
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 10
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000001475 halogen functional group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 239000001630 malic acid Substances 0.000 claims description 10
- 235000011090 malic acid Nutrition 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 9
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 9
- 235000015165 citric acid Nutrition 0.000 claims description 9
- 239000011975 tartaric acid Substances 0.000 claims description 9
- 235000002906 tartaric acid Nutrition 0.000 claims description 9
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 claims description 8
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 8
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims description 8
- 235000006408 oxalic acid Nutrition 0.000 claims description 8
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 8
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 7
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 7
- 239000005639 Lauric acid Substances 0.000 claims description 7
- 235000021314 Palmitic acid Nutrition 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- 229960002446 octanoic acid Drugs 0.000 claims description 7
- 239000008117 stearic acid Substances 0.000 claims description 7
- 229960001367 tartaric acid Drugs 0.000 claims description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 6
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 6
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- 239000005642 Oleic acid Substances 0.000 claims description 6
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 6
- 229910052786 argon Inorganic materials 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 150000007942 carboxylates Chemical class 0.000 claims description 6
- 125000000524 functional group Chemical group 0.000 claims description 6
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 6
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 claims description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 6
- 229960002969 oleic acid Drugs 0.000 claims description 6
- 235000021313 oleic acid Nutrition 0.000 claims description 6
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- ARCGXLSVLAOJQL-UHFFFAOYSA-N trimellitic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(C(O)=O)=C1 ARCGXLSVLAOJQL-UHFFFAOYSA-N 0.000 claims description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 6
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 5
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 5
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 5
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 5
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 5
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 4
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 235000021357 Behenic acid Nutrition 0.000 claims description 4
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 4
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 4
- 235000021319 Palmitoleic acid Nutrition 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 239000001361 adipic acid Substances 0.000 claims description 4
- 235000011037 adipic acid Nutrition 0.000 claims description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 229940114079 arachidonic acid Drugs 0.000 claims description 4
- 235000021342 arachidonic acid Nutrition 0.000 claims description 4
- 150000004982 aromatic amines Chemical class 0.000 claims description 4
- 229940116226 behenic acid Drugs 0.000 claims description 4
- UJMDYLWCYJJYMO-UHFFFAOYSA-N benzene-1,2,3-tricarboxylic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1C(O)=O UJMDYLWCYJJYMO-UHFFFAOYSA-N 0.000 claims description 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 4
- 239000001569 carbon dioxide Substances 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 4
- 229960004106 citric acid Drugs 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims description 4
- 229960000304 folic acid Drugs 0.000 claims description 4
- 235000019152 folic acid Nutrition 0.000 claims description 4
- 239000011724 folic acid Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960004232 linoleic acid Drugs 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 239000011976 maleic acid Substances 0.000 claims description 4
- 229940099690 malic acid Drugs 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 229940055726 pantothenic acid Drugs 0.000 claims description 4
- 235000019161 pantothenic acid Nutrition 0.000 claims description 4
- 239000011713 pantothenic acid Substances 0.000 claims description 4
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 claims description 4
- 125000003367 polycyclic group Chemical group 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 229930002330 retinoic acid Natural products 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 claims description 4
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 4
- 229960001727 tretinoin Drugs 0.000 claims description 4
- 229910016962 As(SH)3 Inorganic materials 0.000 claims description 3
- 229910017252 AsO3H Inorganic materials 0.000 claims description 3
- 229910017258 AsO4H Inorganic materials 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 3
- 229910005942 Ge(OH)3 Inorganic materials 0.000 claims description 3
- 229910005927 Ge(SH)4 Inorganic materials 0.000 claims description 3
- 229910004841 P(SH)3 Inorganic materials 0.000 claims description 3
- 229910018830 PO3H Inorganic materials 0.000 claims description 3
- 229910006069 SO3H Inorganic materials 0.000 claims description 3
- 229910007157 Si(OH)3 Inorganic materials 0.000 claims description 3
- 229910007215 Si(SH)4 Inorganic materials 0.000 claims description 3
- 229910009241 Sn(SH)4 Inorganic materials 0.000 claims description 3
- 235000011054 acetic acid Nutrition 0.000 claims description 3
- 229960000583 acetic acid Drugs 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 3
- 239000000032 diagnostic agent Substances 0.000 claims description 3
- 229940039227 diagnostic agent Drugs 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 3
- 229940098695 palmitic acid Drugs 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 229960004274 stearic acid Drugs 0.000 claims description 3
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 229940005605 valeric acid Drugs 0.000 claims description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 2
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 claims description 2
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 claims description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 2
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 claims description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims description 2
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 claims description 2
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 2
- 229940091181 aconitic acid Drugs 0.000 claims description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 claims description 2
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 claims description 2
- 238000012377 drug delivery Methods 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- FPIQZBQZKBKLEI-UHFFFAOYSA-N ethyl 1-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylate Chemical compound ClCCN(N=O)C(=O)NC1(C(=O)OCC)CCCCC1 FPIQZBQZKBKLEI-UHFFFAOYSA-N 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004488 linolenic acid Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 2
- 229960002510 mandelic acid Drugs 0.000 claims description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims description 2
- 229940014800 succinic anhydride Drugs 0.000 claims description 2
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 claims description 2
- 150000003628 tricarboxylic acids Chemical class 0.000 claims description 2
- KQTIIICEAUMSDG-UHFFFAOYSA-N tricarballylic acid Chemical compound OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 claims 5
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 claims 1
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 claims 1
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 claims 1
- 239000005643 Pelargonic acid Substances 0.000 claims 1
- 229940124447 delivery agent Drugs 0.000 claims 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 150000004715 keto acids Chemical class 0.000 claims 1
- 229940033355 lauric acid Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910044991 metal oxide Inorganic materials 0.000 claims 1
- 150000004706 metal oxides Chemical class 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 229940107700 pyruvic acid Drugs 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 239000000796 flavoring agent Substances 0.000 abstract description 3
- 238000006555 catalytic reaction Methods 0.000 abstract description 2
- 239000002274 desiccant Substances 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 239000007858 starting material Substances 0.000 abstract description 2
- 241000894007 species Species 0.000 description 20
- 239000011777 magnesium Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 125000005647 linker group Chemical group 0.000 description 15
- MFUVDXOKPBAHMC-UHFFFAOYSA-N magnesium;dinitrate;hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MFUVDXOKPBAHMC-UHFFFAOYSA-N 0.000 description 12
- 238000001179 sorption measurement Methods 0.000 description 12
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 10
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- 229910002651 NO3 Inorganic materials 0.000 description 9
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 239000000945 filler Substances 0.000 description 9
- 239000008247 solid mixture Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 8
- 229910052749 magnesium Inorganic materials 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000002243 precursor Substances 0.000 description 7
- DJHGAFSJWGLOIV-UHFFFAOYSA-L Arsenate2- Chemical compound O[As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-L 0.000 description 6
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- DKSMCEUSSQTGBK-UHFFFAOYSA-M bromite Chemical compound [O-]Br=O DKSMCEUSSQTGBK-UHFFFAOYSA-M 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Chemical compound Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 description 6
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 6
- LLYCMZGLHLKPPU-UHFFFAOYSA-M perbromate Chemical compound [O-]Br(=O)(=O)=O LLYCMZGLHLKPPU-UHFFFAOYSA-M 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000011800 void material Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 239000001177 diphosphate Substances 0.000 description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 4
- 235000011180 diphosphates Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910017604 nitric acid Inorganic materials 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- SATWKVZGMWCXOJ-UHFFFAOYSA-N 4-[3,5-bis(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC(C=2C=CC(=CC=2)C(O)=O)=CC(C=2C=CC(=CC=2)C(O)=O)=C1 SATWKVZGMWCXOJ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 3
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 3
- 229940000489 arsenate Drugs 0.000 description 3
- DJHGAFSJWGLOIV-UHFFFAOYSA-M arsenate(1-) Chemical compound O[As](O)([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-M 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 235000010338 boric acid Nutrition 0.000 description 3
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 3
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 3
- 229910001919 chlorite Inorganic materials 0.000 description 3
- 229910052619 chlorite group Inorganic materials 0.000 description 3
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 3
- 229940043279 diisopropylamine Drugs 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- QYHFIVBSNOWOCQ-UHFFFAOYSA-M hydrogenselenate Chemical compound O[Se]([O-])(=O)=O QYHFIVBSNOWOCQ-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 3
- AAUNBWYUJICUKP-UHFFFAOYSA-N hypoiodite Chemical compound I[O-] AAUNBWYUJICUKP-UHFFFAOYSA-N 0.000 description 3
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 3
- 229940097364 magnesium acetate tetrahydrate Drugs 0.000 description 3
- XKPKPGCRSHFTKM-UHFFFAOYSA-L magnesium;diacetate;tetrahydrate Chemical compound O.O.O.O.[Mg+2].CC([O-])=O.CC([O-])=O XKPKPGCRSHFTKM-UHFFFAOYSA-L 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000004767 nitrides Chemical class 0.000 description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 3
- 150000003346 selenoethers Chemical class 0.000 description 3
- XHGGEBRKUWZHEK-UHFFFAOYSA-L tellurate Chemical compound [O-][Te]([O-])(=O)=O XHGGEBRKUWZHEK-UHFFFAOYSA-L 0.000 description 3
- XSOKHXFFCGXDJZ-UHFFFAOYSA-N telluride(2-) Chemical compound [Te-2] XSOKHXFFCGXDJZ-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 3
- HPYNZHMRTTWQTB-UHFFFAOYSA-N 2,3-dimethylpyridine Chemical compound CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 2
- OYFRNYNHAZOYNF-UHFFFAOYSA-N 2,5-dihydroxyterephthalic acid Chemical compound OC(=O)C1=CC(O)=C(C(O)=O)C=C1O OYFRNYNHAZOYNF-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000002156 adsorbate Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001449 anionic compounds Chemical class 0.000 description 2
- PXKLMJQFEQBVLD-UHFFFAOYSA-N bisphenol F Chemical compound C1=CC(O)=CC=C1CC1=CC=C(O)C=C1 PXKLMJQFEQBVLD-UHFFFAOYSA-N 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- DIKBFYAXUHHXCS-UHFFFAOYSA-N bromoform Chemical compound BrC(Br)Br DIKBFYAXUHHXCS-UHFFFAOYSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 229910001412 inorganic anion Inorganic materials 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- XXQBEVHPUKOQEO-UHFFFAOYSA-N potassium superoxide Chemical compound [K+].[K+].[O-][O-] XXQBEVHPUKOQEO-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 2
- DJKGDNKYTKCJKD-BPOCMEKLSA-N (1s,4r,5s,6r)-1,2,3,4,7,7-hexachlorobicyclo[2.2.1]hept-2-ene-5,6-dicarboxylic acid Chemical compound ClC1=C(Cl)[C@]2(Cl)[C@H](C(=O)O)[C@H](C(O)=O)[C@@]1(Cl)C2(Cl)Cl DJKGDNKYTKCJKD-BPOCMEKLSA-N 0.000 description 1
- GGAUUQHSCNMCAU-ZXZARUISSA-N (2s,3r)-butane-1,2,3,4-tetracarboxylic acid Chemical compound OC(=O)C[C@H](C(O)=O)[C@H](C(O)=O)CC(O)=O GGAUUQHSCNMCAU-ZXZARUISSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- XIRDTMSOGDWMOX-UHFFFAOYSA-N 3,4,5,6-tetrabromophthalic acid Chemical compound OC(=O)C1=C(Br)C(Br)=C(Br)C(Br)=C1C(O)=O XIRDTMSOGDWMOX-UHFFFAOYSA-N 0.000 description 1
- WZHHYIOUKQNLQM-UHFFFAOYSA-N 3,4,5,6-tetrachlorophthalic acid Chemical compound OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C(O)=O WZHHYIOUKQNLQM-UHFFFAOYSA-N 0.000 description 1
- WVDRSXGPQWNUBN-UHFFFAOYSA-N 4-(4-carboxyphenoxy)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1OC1=CC=C(C(O)=O)C=C1 WVDRSXGPQWNUBN-UHFFFAOYSA-N 0.000 description 1
- GIOGDFDFBQHXEG-UHFFFAOYSA-N C1=CC=CC=C1.C(=O)(O)C1(CC=CC=C1)C1=CC=CC=C1 Chemical compound C1=CC=CC=C1.C(=O)(O)C1(CC=CC=C1)C1=CC=CC=C1 GIOGDFDFBQHXEG-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- QNVNLUSHGRBCLO-UHFFFAOYSA-N H2BDC Natural products OC(=O)C1=CC(O)=CC(C(O)=O)=C1 QNVNLUSHGRBCLO-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 229950005228 bromoform Drugs 0.000 description 1
- ZNFNDZCXTPWRLQ-UHFFFAOYSA-N butane-1,1,1-tricarboxylic acid Chemical compound CCCC(C(O)=O)(C(O)=O)C(O)=O ZNFNDZCXTPWRLQ-UHFFFAOYSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 229940018557 citraconic acid Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- IFDVQVHZEKPUSC-UHFFFAOYSA-N cyclohex-3-ene-1,2-dicarboxylic acid Chemical compound OC(=O)C1CCC=CC1C(O)=O IFDVQVHZEKPUSC-UHFFFAOYSA-N 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HNEGQIOMVPPMNR-NSCUHMNNSA-N mesaconic acid Chemical compound OC(=O)C(/C)=C/C(O)=O HNEGQIOMVPPMNR-NSCUHMNNSA-N 0.000 description 1
- 229940073584 methylene chloride Drugs 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- HNEGQIOMVPPMNR-UHFFFAOYSA-N methylfumaric acid Natural products OC(=O)C(C)=CC(O)=O HNEGQIOMVPPMNR-UHFFFAOYSA-N 0.000 description 1
- 239000012229 microporous material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011232 storage material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000003784 tall oil Substances 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 125000006158 tetracarboxylic acid group Chemical group 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- UFDHBDMSHIXOKF-UHFFFAOYSA-N tetrahydrophthalic acid Natural products OC(=O)C1=C(C(O)=O)CCCC1 UFDHBDMSHIXOKF-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F17—STORING OR DISTRIBUTING GASES OR LIQUIDS
- F17C—VESSELS FOR CONTAINING OR STORING COMPRESSED, LIQUEFIED OR SOLIDIFIED GASES; FIXED-CAPACITY GAS-HOLDERS; FILLING VESSELS WITH, OR DISCHARGING FROM VESSELS, COMPRESSED, LIQUEFIED, OR SOLIDIFIED GASES
- F17C11/00—Use of gas-solvents or gas-sorbents in vessels
- F17C11/005—Use of gas-solvents or gas-sorbents in vessels for hydrogen
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/223—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material containing metals, e.g. organo-metallic compounds, coordination complexes
- B01J20/226—Coordination polymers, e.g. metal-organic frameworks [MOF], zeolitic imidazolate frameworks [ZIF]
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B3/00—Hydrogen; Gaseous mixtures containing hydrogen; Separation of hydrogen from mixtures containing it; Purification of hydrogen
- C01B3/0005—Reversible uptake of hydrogen by an appropriate medium, i.e. based on physical or chemical sorption phenomena or on reversible chemical reactions, e.g. for hydrogen storage purposes ; Reversible gettering of hydrogen; Reversible uptake of hydrogen by electrodes
- C01B3/001—Reversible uptake of hydrogen by an appropriate medium, i.e. based on physical or chemical sorption phenomena or on reversible chemical reactions, e.g. for hydrogen storage purposes ; Reversible gettering of hydrogen; Reversible uptake of hydrogen by electrodes characterised by the uptaking medium; Treatment thereof
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B3/00—Hydrogen; Gaseous mixtures containing hydrogen; Separation of hydrogen from mixtures containing it; Purification of hydrogen
- C01B3/0005—Reversible uptake of hydrogen by an appropriate medium, i.e. based on physical or chemical sorption phenomena or on reversible chemical reactions, e.g. for hydrogen storage purposes ; Reversible gettering of hydrogen; Reversible uptake of hydrogen by electrodes
- C01B3/001—Reversible uptake of hydrogen by an appropriate medium, i.e. based on physical or chemical sorption phenomena or on reversible chemical reactions, e.g. for hydrogen storage purposes ; Reversible gettering of hydrogen; Reversible uptake of hydrogen by electrodes characterised by the uptaking medium; Treatment thereof
- C01B3/0015—Organic compounds; Solutions thereof
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B3/00—Hydrogen; Gaseous mixtures containing hydrogen; Separation of hydrogen from mixtures containing it; Purification of hydrogen
- C01B3/0005—Reversible uptake of hydrogen by an appropriate medium, i.e. based on physical or chemical sorption phenomena or on reversible chemical reactions, e.g. for hydrogen storage purposes ; Reversible gettering of hydrogen; Reversible uptake of hydrogen by electrodes
- C01B3/001—Reversible uptake of hydrogen by an appropriate medium, i.e. based on physical or chemical sorption phenomena or on reversible chemical reactions, e.g. for hydrogen storage purposes ; Reversible gettering of hydrogen; Reversible uptake of hydrogen by electrodes characterised by the uptaking medium; Treatment thereof
- C01B3/0031—Intermetallic compounds; Metal alloys; Treatment thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/003—Compounds containing elements of Groups 2 or 12 of the Periodic Table without C-Metal linkages
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F17—STORING OR DISTRIBUTING GASES OR LIQUIDS
- F17C—VESSELS FOR CONTAINING OR STORING COMPRESSED, LIQUEFIED OR SOLIDIFIED GASES; FIXED-CAPACITY GAS-HOLDERS; FILLING VESSELS WITH, OR DISCHARGING FROM VESSELS, COMPRESSED, LIQUEFIED, OR SOLIDIFIED GASES
- F17C11/00—Use of gas-solvents or gas-sorbents in vessels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2251/00—Reactants
- B01D2251/40—Alkaline earth metal or magnesium compounds
- B01D2251/402—Alkaline earth metal or magnesium compounds of magnesium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2251/00—Reactants
- B01D2251/40—Alkaline earth metal or magnesium compounds
- B01D2251/404—Alkaline earth metal or magnesium compounds of calcium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2253/00—Adsorbents used in seperation treatment of gases and vapours
- B01D2253/20—Organic adsorbents
- B01D2253/204—Metal organic frameworks (MOF's)
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2259/00—Type of treatment
- B01D2259/45—Gas separation or purification devices adapted for specific applications
- B01D2259/4525—Gas separation or purification devices adapted for specific applications for storage and dispensing systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/30—Hydrogen technology
- Y02E60/32—Hydrogen storage
Definitions
- the disclosure relates generally to materials that comprised metal organic frameworks.
- the disclosure also relates to materials that are useful to deliver molecules in a biological system as well as biological sensors.
- the disclosure provides porous biocompatible metal organic frameworks (bMOFs) developed from non-toxic starting materials.
- bMOFs metal organic frameworks
- Such bMOF materials can be utilized in drug storage and delivery, flavoring and drying agents in food, catalysis, tissue engineering, dietary supplements, separation technology and gas storage.
- the disclosure provides routes for the design and synthesis of 1, 2 and 3D-biologically useful bMOFs.
- the 3D- bMOFs of the disclosure are porous and capable of storing, within the pores of the framework, drugs; absorbing biomolecules; being used as a framework for tissue engineering and scaffolds; expansion within the gastrointestinal tract to serve as a dietary supplement; and the like.
- the materials described in the disclosure can be tailored as 2D- or 3D- networks depending upon the metal ions, organic linkers and reaction conditions. With selection of the organic linkers, which represents an integral part of the framework, and reaction conditions such as temperature, pH, solvent systems, reactant ratio and reaction time, the desired framework can be achieved.
- the disclosure provides a biocompatible metal- organic framework (bMOF) comprising: a plurality of biocompatible metallic cores, each core linked to at least one other core; a plurality of biocompatible linking ligands that connects adjacent cores, and a plurality of pores, wherein the plurality of linked cores defines the pore.
- the plurality of cores are different. In one aspect. At least two of the cores are different.
- the plurality of linking ligands are different.
- the porous framework is functionalized to bind an analyte or guest species.
- the pores may be heterogeneous or homogenous in size.
- the disclosure also provides a biocompatible/environmentally friendly metal-organic framework comprising: a plurality of metal clusters, each metal cluster comprising one or more metal ions; and a plurality of non toxic charged multidentate linking ligands that connect adjacent metal clusters.
- the linking ligand comprises an alkyl or cycloalkyl group, consisting of 1 to 20 carbon atoms, an aryl group, consisting of 1 to 5 phenyl rings, or an alkyl or aryl amine, consisting of alkyl or cycloalkyl groups having from 1 to 20 carbon atoms or aryl groups consisting of 1 to 5 phenyl rings, and in which multidentate functional groups are covalently bound to the substructure of the ligand.
- Multidentate functionality can be obtained using a member selected from the group consisting of CO 2 H, CS 2 H, NO 2 , SO 3 H, Si(OH) 3 , Ge(OH) 3 , Sn(OH) 3 , Si(SH) 4 , Ge(SH) 4 , Sn(SH) 4 , PO 3 H, AsO 3 H, AsO 4 H, P(SH) 3 , As(SH) 3 , CH(RSH) 2 , C(RSH) 3 , CH (RNH 2 ) 2 , C (RNH 2 ) 3 , CH(ROH) 2 , C(ROH) 3 , CH(RCN) 2 , C(RCN) 3 , wherein R is an alkyl group having from 1 to 5 carbon atoms, or an aryl group consisting of 1 to 2 phenyl rings; and, CH(SH) 2 , C(SH) 3 , CH (NH 2 ) 2, C (NH 2 ) 3, CH(OH) 2 , C(OH) 3
- the linking moiety/ligand comprise carboxylic acid functional groups.
- This disclosure further includes cycloalkyl or aryl substructure that comprise from 1 to 5 rings that include either all carbon or a mixture of carbon, with nitrogen, oxygen, sulfur, boron, phosphorous, silicon and aluminum atoms making up the ring.
- each ligand of the plurality of multidentate linking ligands includes two or more carboxylates .
- the metal ions are selected from the group consisting of Li + , Na + , Rb + , Mg 2+ , Ca 2+ , Sr 2+ , Ba 2+ , Sc 3+ , Ti 4+ , Zr 4+ , Ta 3+ , Cr 3+ , Mo 3+ , W 3+ , Mn 3+ , Fe 3+ , Fe 2+ , Ru 3+ , Ru 2+ , Os 3+ , Os 2+ , Co 3+ , Co 2+ , Ni 2+ , Ni + , Pd 2+ , Pd + , Pt 2+ , Pt + , Cu 2+ , Cu + , Au + , Zn 2+ , Al 3+ , Ga 3+ , In 3+ , Si 4+ , Si 2+ , Ge 4+ , Ge 2+ ,
- the multidentate linking ligand has 6 or more atoms (e.g., twelve or more atoms) that are incorporated in aromatic rings or non-aromatic rings.
- the one or more multidentate linking ligands can comprise anions of parent compounds selected from the group consisting of citric acid, malic acid, tartaric acid, retinoic acid, pantothenic acid, folic acid, irrigationtinic acid, oxalic acid, butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, myristoleic acid, palmitoleic acid, oleic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid, and docosahexaenoic acid.
- the disclosure provides a framework comprising of citric acid,
- M is a non-toxic metal and R is selected from the group consisting of -H, -OH, -ORl, aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo, wherein Rl can be -H, and aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo.
- M is a non-toxic metal and wherein n is 0, 1, or 2.
- the bMOFs of the disclosure can further comprise a guest species; the guest species can increase the surface area of the MOF.
- the guest species is a biological agent (e.g., a protein, polypeptide, peptide, lipid, nucleic acid or small molecule agent) .
- the biological agent is a therapeutic agent or a diagnostic agent .
- the disclosure also provides a dietary supplement comprising a bMOF of the disclosure.
- bMOFs are biocompatible and can be used for delivery of a drug or other biological agent or adsorption of a biological agent within the gastrointestinal tract.
- the bMOF may be rendered expandable by absorption of a guest species within the gastrointestinal tract or made such that the framework is biodegradable during a desired time period there by, for example, giving the stimulus of being satiated.
- the disclosure provides a drug delivery composition comprising a bMOF having within its pores a drug, wherein the drug is delivered to the intestinal tract (e.g., an enteric coating) .
- a food additive comprising a bMOF of the disclosure is provided.
- the disclosure also provides a gas storage device comprising a MOF of the disclosure.
- a gas storage device comprising a MOF of the disclosure.
- DESCRIPTION OF DRAWINGS [0016]
- Figure 1 shows characterization of a MOF of the disclosure .
- Figure 2 shows characterization of a MOF of the disclosure .
- Figure 3A-B shows a bMOF structure (MgBDCl) of the disclosure.
- A Binuclear cluster in MgBDC-I including Magnesium; Oxygen; and Carbon atoms.
- B 3D view of MgBDC-I.
- Figure 4A-B shows a bMOF structure (MgDHBDC-I) of the disclosure
- A Hexanuclear cluster in MgDHBDC-I including Magnesium; Oxygen; and Carbon atoms.
- B 3D view of MgDHBDC- 1.
- Figure 5 shows an MgOBA-I structure of the disclosure including Magnesium; Oxygen; and Carbon atoms.
- Figure 6A-B shows a bMOF structure of the disclosure (MgBTC-I) .
- A) shows a binuclear cluster of MgBTC-I including Magnesium; Oxygen; and Carbon.
- B) shows Trigonal links are represented as dark triangles, while light gray triangles represent inorganic SBUs. Empty spaces are illustrated as spheres.
- Figure 7 shows a bMOF (MgBTB-I) framework of the disclosure.
- An Octahedral Inorganic SBUs and tritopic links form 2D layer structure.
- Figure 8A-B shows a bMOF structure of the disclosure (MgBTB-2) .
- MgBTB-2 Fundamental building units of MgBTB-2 including Magnesium; Oxygen; Carbon; and Nitrogen.
- B Trigonal links are represented as triangles, while cubes represent inorganic SBUs. Empty spaces are illustrated as spheres .
- Figure 9A-B shows a bMOF of the disclosure (MgBTB- 3) .
- A Fundamental building units of MgBTB-3 including Magnesium; Oxygen; Carbon; and Nitrogen.
- B Inorganic SBUs are represented as squares. Empty spaces are illustrated as spheres .
- Figure 10 shows a bMOF of the disclosure (MgBTB-4). The structure consists of two types of inorganic SBUs (light and dark triangles and octahedra) and trigonal links. Empty spaces are illustrated as spheres.
- FIG 11A-B shows yet another bMOF of the disclosure (MgBBC-I) .
- (B) shows a space fill model of the 2D structure.
- MOFs comprising using non-toxic components as a drug storage and delivery material has not been reported nor the synthesis of biologically non-toxic MOFs.
- An advantage of the MOFs of the disclosure compared to previous MOFs is the non-toxic nature of the composition.
- the MOFs are highly stable with or without the presence of a guest molecule within the pores of the framework.
- a “cluster” refers to a repeating unit or units found in a framework.
- Such a framework can comprise a homogenous repeating cluster or a heterogeneous repeating cluster structure.
- a cluster comprises a transition metal and a linking moiety (sometimes referred to as a linking ligand) .
- a plurality of clusters linked together defines a framework.
- linking moiety refers to a mono-dentate, bidentate or multidentate compound that bind a biocompatible metal or a plurality of biocompatible metals, respectively.
- linking ligand or “linking moiety” refers to a chemical species (including neutral molecules and ions) that coordinate two or more metals and the definition of void regions or channels in the framework that is produced.
- the linking ligand of the disclosure is a non-toxic molecule. Examples of a linking ligand useful in the methods and compositions of the disclosure include citric acid, malic acid, and tartaric acid.
- linking moieties or ligands include, for example, methanoic acid, ethanoic acid, propanoic acid, butanoic acid, valeric acid, caproic acid, caprylic acid, capric acid, lauric acid, mylistic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, cyclohexanecarboxylic acid, phenylacetic acid, benzoic acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, maleic acid, fumaric acid, phthalic acid, isophthalic acid, terephthalic acid, hemimellitic acid, trimellitic acid, trimesic acid, succinic anhydride, maleic anhydride, phthalic anhydride, glycolic acid, lactic acid, hydroxybutyric acid, mandelic acid, glyceric acid
- a linking moiety/ligand can comprise an alkyl or cycloalkyl group, consisting of 1 to 20 carbon atoms, an aryl group, consisting of 1 to 5 phenyl rings, or an alkyl or aryl amine, consisting of alkyl or cycloalkyl groups having from I to 20 carbon atoms or aryl groups consisting of 1 to 5 phenyl rings, and in which multidentate functional groups are covalently bound to the substructure of the ligand.
- Multidentate functionality can be selected from the group consisting of CO 2 H, CS 2 H, NO 2 , SO 3 H, Si(OH) 3 , Ge(OH) 3 , Sn(OH) 3 , Si(SH) 4 , Ge(SH) 4 , Sn(SH) 4 , PO 3 H, AsO 3 H, AsO 4 H, P(SH) 3 , As(SH) 3 , CH(RSH) 2 , C(RSH) 3 , CH (RNH 2 ) 2 , C (RNH 2 ) 3 , CH(ROH) 2 , C(ROH) 3 , CH(RCN) 2 , C(RCN) 3 , wherein R is an alkyl group having from 1 to 5 carbon atoms, or an aryl group consisting of 1 to 2 phenyl rings; and, CH(SH) 2 , C(SH) 3 , CH (NH 2 ) 2 , C (NH 2 ) 3 , CH(OH) 2 , C(OH) 3
- the linking moiety/ligand comprise carboxylic acid functional groups.
- This disclosure further includes cycloalkyl or aryl substructure that comprise from 1 to 5 rings that include either all carbon or a mixture of carbon, with nitrogen, oxygen, sulfur, boron, phosphorous, silicon and aluminum atoms making up the ring.
- crystalline metal-organic microporous materials can be synthesized by the addition of a solution of a metal salt to a solution containing an appropriate blend of ligands, some of which contain multidentate functional groups, as described herein, and others of which contain monodentate functional groups, in the presence of a suitable templating agent.
- the linking ligand comprises one or more carboxylates .
- the linking ligand may be a polycarboxylic acid.
- polycarboxylic acid indicates a dicarboxylic, tricarboxylic, tetracarboxylic, pentacarboxylic, and like monomeric polycarboxylic acids, and anhydrides, and combinations thereof, as well as polymeric polycarboxylic acids, anhydrides, copolymers, and combinations thereof.
- a monomeric polycarboxylic acid may be a dicarboxylic acid, including, but not limited to, unsaturated aliphatic dicarboxylic acids, saturated aliphatic dicarboxylic acids, aromatic dicarboxylic acids, unsaturated cyclic dicarboxylic acids, saturated cyclic dicarboxylic acids, hydroxy-substituted derivatives thereof, and the like.
- the polycarboxylic acid(s) itself may be a tricarboxylic acid, including, but not limited to, unsaturated aliphatic tricarboxylic acids, saturated aliphatic tricarboxylic acids, aromatic tricarboxylic acids, unsaturated cyclic tricarboxylic acids, saturated cyclic tricarboxylic acids, hydroxy-substituted derivatives thereof, and the like. It is appreciated that any such polycarboxylic acids may be optionally substituted, such as with hydroxy, halo, alkyl, alkoxy, and the like. In one variation, the polycarboxylic acid is the saturated aliphatic tricarboxylic acid, citric acid.
- polycarboxylic acids include, but are not limited to, aconitic acid, adipic acid, azelaic acid, butane tetracarboxylic acid dihydride, butane tricarboxylic acid, chlorendic acid, citraconic acid, dicyclopentadiene-maleic acid adducts, diethylenetriamine pentaacetic acid, adducts of dipentene and maleic acid, ethylenediamine tetraacetic acid (EDTA) , fully maleated rosin, maleated tall-oil fatty acids, fumaric acid, glutaric acid, isophthalic acid, itaconic acid, maleated rosin oxidized with potassium peroxide to alcohol then carboxylic acid, maleic acid, malic acid, mesaconic acid, biphenol A or bisphenol F reacted to introduce 3-4 carboxyl groups, oxalic acid, phthalic acid, sebacic acid, succinic acid,
- the disclosure provides a cluster comprising a metal ion and a linking ligand having a general structure selected from the group consisting of:
- M is a non-toxic metal and R is selected from the group consisting of -H, -OH, -ORl, aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo, wherein Rl can be -H, and aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo.
- linking moieties can be modified or derivatized.
- the linking moiety as set forth in Formula II can be modified as follows:
- each of Rl-15 are independently selected from the group consisting of -H, -OH, -OR 16 , aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo, wherein R 16 can be -H, and aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo.
- alkyl refers to a saturated monovalent chain of carbon atoms, which may be optionally branched;
- cycloalkyl refers to a monovalent chain of carbon atoms, a portion of which forms a ring;
- alkenyl refers to an unsaturated monovalent chain of carbon atoms including at least one double bond, which may be optionally branched;
- cycloalkenyl refers to an unsaturated monovalent chain of carbon atoms, a portion of which forms a ring;
- heterocyclyl refers to a monovalent chain of carbon and heteroatoms, wherein the heteroatoms are selected from nitrogen, oxygen, and sulfur, a portion of which, including at least one heteroatom, form a ring;
- aryl refers to an aromatic mono or polycyclic ring of carbon atoms, such as phenyl, naphthyl, and the like; and the term "heteroaryl
- each of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and heterocyclyl may be optionally substituted with independently selected groups such as alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, carboxylic acid and derivatives thereof, including esters, amides, and nitriles, hydroxy, alkoxy, acyloxy, amino, alkyl and dialkylamino, acylamino, thio, and the like, and combinations thereof.
- each of aryl and heteroaryl may be optionally substituted with one or more independently selected substituents, such as halo, hydroxy, amino, alkyl or dialkylamino, alkoxy, alkylsulfonyl, cyano, nitro, and the like.
- the disclosure also provides a biocompatible metal- organic framework (bMOF) comprising a homogenous or heterogeneous plurality of clusters, wherein the clusters form a framework.
- bMOF biocompatible metal- organic framework
- a "framework,” as used herein, refers to a framework of repeating clusters having a 2-D or 3-D structure .
- non-toxic chemical species refers to a chemical that when contacted with a biological organism does not have, or has limited, direct effect on cell apoptosis or death. Such materials can also be referred to as biologically safe, biologically inert, and biocompatible.
- non-linking ligand means a chemical species that is coordinated to a metal but does not act as a linker.
- guest means any chemical species that resides within the void regions of an open framework solid that is not considered integral to the framework. Examples include: molecules of the solvent that fill the void regions during the synthetic process, other molecules that are exchanged for the solvent such as during immersion (via diffusion) or after evacuation of the solvent molecules, such as gases in a sorption experiment.
- a guest species may be a drug, therapeutic agent or diagnostic agent to be “carried” by the framework of the disclosure.
- a chemical species is used herein to include peptides, polypeptides, nucleic acid molecules, and fatty acids.
- a drug will comprise a small organic molecule capable of filling or partially filling a void of a framework.
- the framework can be used as a scaffold for tissue engineering, wherein the framework may be infiltrate by cells or extracellular matrix material (e.g., collagen, elastin and the like) such that it support cell growth. Because the framework is biocompatible cells can grow and proliferate on the framework.
- charge-balancing species means a charged guest species that balances the charge of the framework. Quite often this species is strongly bound to the framework, i.e. via hydrogen bonds. It may decompose upon evacuation to leave a smaller charged species, or be exchanged for an equivalently charged species, but typically it cannot be removed from the pore of a metal-organic framework without collapse.
- space-filling agent means a guest species that fills the void regions of an open framework during synthesis. Materials that exhibit permanent porosity remain intact after removal of the space-filling agent via heating and/or evacuation. Examples include: solvent molecules or molecular charge-balancing species. The latter may decompose upon heating, such that their gaseous products are easily evacuated and a smaller charge-balancing species remain in the pore (i.e. protons) . Sometimes space filling agents are referred to as templating agents .
- accessible metal site means a site in a metal cluster and, in particular, a position adjacent to a metal in a metal cluster available for a chemical moiety such as a ligand to attach.
- open metal site means a site in a metal cluster and, in particular, a position adjacent to a metal in a metal cluster from which a ligand or other chemical moiety has been removed, rendering that metal cluster reactive for adsorption of a chemical species having available electron density for attachment to the metal cluster and, in particular, a metal in the metal cluster.
- metal cluster means any metal containing moiety present in a bMOF of the disclosure. This definition embracing single metal atoms or metal ions to groups of metals or metal ions that optionally include ligands or covalently bonded groups.
- a vehicle for delivery of a biological agent to an organism comprising a bMOF.
- the bMOF of the embodiment includes a plurality of metal clusters and a plurality of charged multidentate non-toxic linking ligands that connect adjacent metal clusters.
- Each metal cluster includes one or more metal ions and at least one open metal site.
- the bMOF includes one or more sites for capturing/binding molecule to be delivered to an organism (e.g., a mammal, including a human) .
- the one or more sites include the at least one open metal site.
- Biological agents that may be captured/stored in the frameworks of the disclosure include any biological molecules capable of fitting within a pore and comprising available electron density for attachment to the one or more sites.
- Such electron density includes molecules having multiple bonds between two atoms contained therein or molecules having a lone pair of electrons.
- the open metal site is formed by activating a precursor metal-organic framework.
- this activation involves removing one or more chemical moieties from the metal cluster.
- moieties are ligands complexed to or bonded to a metal or metal ion within the metal clusters.
- moieties include species such as water, solvent molecules contained within the metal clusters, and other chemical moieties having electron density available for attachment to the metal cluster and/or metal atoms or ions contained therein.
- electron density includes molecules having multiple bonds between two atoms contained therein or molecules having a lone pair of electrons.
- a biocompatible metal organic framework comprises a plurality of metal cores and a plurality of charged non-toxic multidentate linking ligands that connect adjacent metal clusters.
- Each metal core includes one or more metal ions and at least one accessible metal site.
- the metal ions are typically alkali earth metals and the ligands are biocompatible acids.
- the metal-organic framework includes one or more sites for binding or storing a biological molecule or gas.
- the one or more sites include the at least one accessible metal site.
- Gases that may be stored in the gas storage material of the disclosure include gas molecules comprising available electron density for attachment to the one or more sites for storing gas.
- gases include, but are not limited to, the gases comprising a component selected from the group consisting of ammonia, argon, carbon dioxide, carbon monoxide, hydrogen, and combinations thereof.
- the accessible metal site is an open metal site.
- the metal-organic frameworks used in the embodiments of the disclosure include a plurality of pores for adsorption of a biological molecule or gas.
- the plurality of pores has a unimodal size distribution.
- the plurality of pores have a multimodal (e.g., bimodal) size distribution.
- the metal organic frameworks include metal clusters comprising one or more metal ions.
- the metal-organic frameworks include metal clusters that comprise two or more metal ions.
- the metal-organic frameworks include metal cores that comprise three or more metal ions.
- the metal ions can be selected from the group consisting of Li + , Na + , Rb + , Mg 2+ , Ca 2+ , Sr 2+ , Ba 2+ , Sc 3+ , Ti 4+ , Zr 4+ , Ta 3+ , Cr 3+ , Mo 3+ , W 3+ , Mn 3+ , Fe 3+ , Fe 2+ , Ru 3+ , Ru 2+ , Os 3+ , Os 2+ , Co 3+ , Co 2+ , Ni 2+ , Ni + , Pd 2+ , Pd + , Pt 2+ , Pt + , Cu 2+ , Cu + , Au + , Zn 2+ , Al 3+ , Ga 3+ , In 3+ , Si 4+ , Si 2+ , Ge 4+ , Ge 2+ , Sn 4+ , Sn 2+ , Bi 5+ , Bi 3+ , and combinations thereof .
- An environmentally friendly metal-organic framework of the disclosure comprises a plurality of metal cores, each metal core comprising one or more metal ions; and a plurality of non toxic charged multidentate linking ligands that connect adjacent metal cores.
- the each ligand of the plurality of multidentate linking ligands includes two or more carboxylates .
- the multidentate linking ligand has twelve or more atoms that are incorporated in aromatic rings or non-aromatic rings.
- the one or more multidentate linking ligands comprise anions of parent compounds selected from the group consisting of citric acid, malic acid, tartaric acid, retinoic acid, pantothenic acid, folic acid, irrigationtinic acid, oxalic acid, butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, myristoleic acid, palmitoleic acid, oleic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid, and docosahexaenoic acid.
- the metal-organic framework used in the disclosure optionally further comprises a non-linking ligand.
- the non-linking ligand is selected from the group consisting of 0 2 ⁇ , sulfate, nitrate, nitrite, sulfite, bisulfite, phosphate, hydrogen phosphate, dihydrogen phosphate, diphosphate, triphosphate, phosphite, chloride, chlorate, bromide, bromate, iodide, iodate, carbonate, bicarbonate, sulfide, hydrogen sulphate, selenide, selenate, hydrogen selenate, telluride, tellurate, hydrogen tellurate, nitride, phosphide, arsenide, arsenate, hydrogen arsenate, dihydrogen arsenate, antimonide, antimonate, hydrogen antimonate, dihydrogen antimonate, fluoride, boride, borate, hydrogen borate,
- the metal-organic frameworks of the disclosure optionally further comprise space-filling agents, adsorbed chemical species, guest species, and combinations thereof.
- space-filling agents, adsorbed chemical species and guest species increase the surface area of the metal-organic framework.
- Suitable spacefilling agents include, for example, a component selected from the group consisting of:
- alkyl amines and their corresponding alkyl ammonium salts containing linear, branched, or cyclic aliphatic groups, having from 1 to 20 carbon atoms;
- alkyl phosphonium salts containing linear, branched, or cyclic aliphatic groups, having from 1 to 20 carbon atoms;
- alkyl organic acids and their corresponding salts containing linear, branched, or cyclic aliphatic groups, having from 1 to 20 carbon atoms;
- aryl organic acids and their corresponding salts having from 1 to 5 phenyl rings
- aliphatic alcohols containing linear, branched, or cyclic aliphatic groups, having from 1 to 20 carbon atoms
- inorganic anions from the group consisting of sulfate, nitrate, nitrite, sulfite, bisulfite, phosphate, hydrogen phosphate, dihydrogen phosphate, diphosphate, triphosphate, phosphite, chloride, chlorate, bromide, bromate, iodide, iodate, carbonate, bicarbonate, O.
- adsorbed chemical species include ammonia, carbon dioxide, carbon monoxide, hydrogen, amines, methane, oxygen, argon, nitrogen, argon, organic dyes, polycyclic organic molecules, flavorants, small molecule therapeutics and diagnostics and combinations thereof.
- guest species are organic molecules with a molecular weight less than about 100 g/mol, organic molecules with a molecular weight less than about 300 g/mol, organic molecules with a molecular weight less than about 600 g/mol, organic molecules with a molecular weight greater than about 600 g/mol.
- adsorbed chemical species, guest species, and space-filling agents are introduced in the metal-organic frameworks by contacting the metal-organic frameworks with a pre-selected chemical species, guest species, or space-filling agent.
- the metal organic framework comprises an interpenetrating metal-organic framework that increases the surface area of the metal-organic framework.
- the metal-organic framework is formed by combining a solution comprising a solvent and metal ions selected from the group consisting of Li + , Na + , Rb + , Mg 2+ , Ca 2+ , Sr 2+ , Ba 2+ , Sc 3+ , Ti 4+ , Zr 4+ , Ta 3+ , Cr 3+ , Mo 3+ , W 3+ , Mn 3+ , Fe 3+ , Fe 2+ , Ru 3+ , Ru 2+ , Os 3+ , Os 2+ , Co 3+ , Co 2+ , Ni 2+ , Ni + , Pd 2+ , Pd + , Pt 2+ , Pt + , Cu 2+ , Cu + , Au + , Zn 2+ , Al 3+ , Ga 3+ , In 3+ , Si 4+ , Si 2+ , Ge 4+ , Ge 2+ , Sn 4+ , Sn 2+ , Bi 5+ , Bi 3+
- the multidentate linking ligand can comprise two or more carboxylates or anions of parent compounds selected from the group consisting of citric acid, malic acid, tartaric acid, retinoic acid, pantothenic acid, folic acid, irrigationtinic acid, oxalic acid, butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, myristoleic acid, palmitoleic acid, oleic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid, and docosahexaenoic acid.
- the bMOFs of the disclosure can be formed by using any of Schemes I or II.
- the metal-organic framework used in the disclosure optionally further comprises a non-linking ligand.
- the non-linking ligand is selected from the group consisting of O 2 , sulfate, nitrate, nitrite, sulfite, bisulfite, phosphate, hydrogen phosphate, dihydrogen phosphate, diphosphate, triphosphate, phosphite, chloride, chlorate, bromide, bromate, iodide, iodate, carbonate, bicarbonate, sulfide, hydrogen sulphate, selenide, selenate, hydrogen selenate, telluride, tellurate, hydrogen tellurate, nitride, phosphide, arsenide, arsenate, hydrogen arsenate, dihydrogen arsenate, antimonide, antimonate, hydrogen antimonate, dihydrogen antimonate, fluoride, boride, borate, hydrogen borate, perch
- the one or more ligands are removed by heating the precursor MOF.
- the precursor MOF is heated to a temperature from about 30 0 C to about 300 0 C.
- the one or more ligands are removed by exposing the precursor MOF to a vacuum.
- the vacuum is characterized by having a pressure less than 10 ⁇ 3 torr. In other variations, from about 10 ⁇ 5 torr to about 700 torr.
- the one or more ligands are removed by simultaneously heating the precursor MOF and by exposing the precursor MOF to a vacuum.
- the solution used in the method of the disclosure may also include space-filling agents.
- one or more ligands of the precursor MOF may be exchanged with another ligand or ligands that are more easily removed by subsequent heating and/or exposure to a vacuum.
- the framework set forth above may include an interpenetrating framework that increases the surface area of the framework.
- the frameworks of the disclosure may advantageously exclude such interpenetration, there are circumstances when the inclusion of an interpenetrating framework may be used to increase the surface area.
- the frameworks of the disclosure can be used as sorption devices in vitro or in vivo.
- Sorption is a general term that refers to a process resulting in the association of atoms or molecules with a target material. Sorption includes both adsorption and absorption.
- Absorption refers to a process in which atoms or molecules move into the bulk of a porous material, such as the absorption of water by a sponge.
- Adsorption refers to a process in which atoms or molecules move from a bulk phase (that is, solid, liquid, or gas) onto a solid or liquid surface.
- the term adsorption may be used in the context of solid surfaces in contact with liquids and gases.
- adsorbates Molecules that have been adsorbed onto solid surfaces are referred to generically as adsorbates, and the surface to which they are adsorbed as the substrate or adsorbent.
- Adsorption is usually described through isotherms, that is, functions which connect the amount of adsorbate on the adsorbent, with its pressure (if gas) or concentration (if liquid) .
- desorption refers to the reverse of adsorption, and is a process in which molecules adsorbed on a surface are transferred back into a bulk phase.
- One (1 ) -dimensional, 2D- and 3D- environmentally friendly metal organic frameworks (efMOFs or bMOFs) of the disclosure have been synthesized and characterized by PXRD, X-ray signal crystal determinations and TGA.
- efMOFs or bMOFs metal organic frameworks
- the following synthetic routes can be used to generate certain species of the compositions of the disclosure:
- Figure 1 shows the characterization of Mg 3 (citrate) 2 (H 2 O) 6 -8H 2 O and Ca(MaI) -2H 2 O.
- Figure 2 shows the characterization of Ca 3 (citrate) 2 (H 2 O) 2 -8H 2 O and Ca (Tar) (H 2 O) 2 -2H 2 O.
- MgBDC-I A solid mixture of terephthalic acid (H2BDC, 240 mg) and magnesium nitrate hexahydrate Mg (NO 3 ) 2* 6H 2 O (128 mg) was dissolved in N, N-diethylformamide (13 mL) and 2.0 M aqueous HNO 3 solution (40 ⁇ L) in a 20-mL vial. 60 ⁇ L diisopropylamine and 2 mL DEF was mixed in a 4-mL vial. The 4-mL vial was placed in the 20-mL vial to allow diffusion. The 20-mL vial was capped and placed in an isothermal oven at 85 0 C for 72 h.
- Figure 3 shows a framework of MgBDC-I .
- MgDHBDC-I A solid mixture of 2,5- dihydroxyterephthalic acid (H2DHBDC, 40 mg) and magnesium nitrate hexahydrate Mg (NO 3 ) 2 * 6H 2 O (150 mg) was dissolved in a mixture of N, N-diethylformamide (8 mL) , distilled water (1 mL) and 2.0 M aqueous HNO 3 solution (20 ⁇ L) in a 20-mL vial. 20 ⁇ L diisopropylamine and 2 mL N, N-diethylformamide was mixed in a 4-mL vial. The 4-mL vial was placed in the 20-mL vial to allow diffusion. The 20-mL vial was capped and placed in an isothermal oven at 65 0 C for 60 days.
- Figure 4 shows a framework of MgDHBD-I.
- MgOBA-I A solid mixture of 4 , 4 ' -oxybis (benzoic acid) (H 2 OBA, 50.0 mg) and magnesium nitrate hexahydrate Mg (NO 3 ) 2 ' 6H2O (10.0 mg) was dissolved in N, N-dimthylformamide (5 mL) in a 20-mL vial. 20 ⁇ L diisopropylamine and 2 mL N, N- dimthylformamide was mixed in a 4-mL vial. The 4-mL vial was placed in the 20-mL vial to allow diffusion. The 20-mL vial was capped and placed in an isothermal oven at 65 0 C for 10 days.
- Figure 5 shows a framework of MgOBA-I.
- MgBTC-I A solid mixture of trimesic acid (H3BTC, 50.0 mg) and magnesium nitrate hexahydrate Mg (NO 3 ) 2 • 6H 2 O (150.0 mg) was dissolved in a mixture of N, N- diethylformamide (5 mL) , ethanol (3 mL) and 2-ethyl-l-hexanol (2 mL) in a 20-mL vial. The vial was capped and placed in an isothermal oven at 85 0 C for 3 days.
- Figure 6 shows a framework of MgBTC-I .
- MgBTB-I A solid mixture of 1, 3, 5-tri (4 ' -carboxy- 4 , 4 ' -biphenyl) benzene (H3BTB, 43.5 mg) and magnesium acetate tetrahydrate Mg (OAc) 2 • 4H 2 O (5.0 mg) was dissolved in a mixture of N, N-dimethylacetatmide (3 mL) and dimethylamine (20 ⁇ L) in a 4-mL vial. The vial was capped and placed in an isothermal oven at 120 0 C for 3 days.
- Figure 7 shows a framework of MgBTB-I .
- MgBTB-2 A solid mixture of 1, 3, 5-tri (4 ' -carboxy- 4 , 4 ' -biphenyl) benzene (H3BTB, 43.5 mg) and magnesium acetate tetrahydrate Mg (OAc) 2 • 4H 2 O (5.0 mg) was dissolved in a mixture of N, N-dimethylace
- MgBTB-3 A solid mixture of 4, 4' , 4" -benzene-1, 3, 5- triyl-tri-benzoic acid (H3BTB, 10.0 mg) and magnesium acetate tetrahydrate Mg (OAc) 2 * 4H 2 O (5.0 mg) was dissolved in a mixture of N-methylpyrrolidone (2 mL) and distilled water (1 mL) in a 20-mL vial. 20 ⁇ L triethylamine and 2 mL N-methylpyrrolidone was mixed in a 4-mL vial. The 4-mL vial was placed in the 20- mL vial to allow diffusion. The 20-mL vial was capped and placed in an isothermal oven at 65 0 C for 7 days.
- Figure 9 shows a framework of MgBTB-3.
- MgBTB-4 A solid mixture of 4, 4' , 4" -benzene-1, 3, 5- triyl-tri-benzoic acid (H3BTB, 30.0 mg) and magnesium acetate tetrahydrate Mg (OAc) 2 * 4H 2 O (40.0 mg) was dissolved in a mixture of N, N-diethylformamide (10 mL) and 2.0 M aqueous HNO3 solution (120 ⁇ L) in a 20-mL vial. 10 ⁇ L N, N- diisopropylamine and 2 mL N, N-diethylformamide was mixed in a 4-mL vial. The 4-mL vial was placed in the 20-mL vial to allow diffusion. The 20-mL vial was capped and placed in an isothermal oven at 65 0 C for 7 days.
- Figure 10 shows a framework of MgBTB-5.
- MgBBC-I A solid mixture of 4, 4' , 4" -benzene-1, 3, 5- triyl-tri-biphenylcarboxylic acid (H3BBC, 30.0 mg) and magnesium nitrate hexahydrate Mg (NO 3 ) 2 • 6H 2 O (4.0 mg) was dissolved in a mixture of N, N-diethylformamide (1.5 mL) , distilled water (0.30 mL) and 2M aqueous HNO 3 solution (20 ⁇ L) in a 4-mL vial. The vial was capped and placed in an isothermal oven at 100 0 C for 5 days.
- Figure 11 shows a framework of MgBBC-I .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Combustion & Propulsion (AREA)
- General Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Analytical Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
This disclosure relates to porous biocompatible metal organic frameworks (bMOFs) developed from non-toxic starting materials. In addition, the bMOF materials can be tailored as 2D- or 3D- networks depending upon the metal ions, organic linkers and reaction conditions. The disclosure also provides bMOF materials that are useful to store and separate biological agents that are environmentally friendly and biocompatible. Further, the bMOF materials can be utilized in drug storage and delivery, flavoring and drying agents in food, catalysis, tissue engineering, dietary supplements, separation technology and gas storage.
Description
EDIBLE AND BIOCOMPATIBLE METAL-ORGANIC FRAMEWORKS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority under 35 U. S. C. §119 to U.S. Provisional Application Serial No. 60/975,089, filed September 25, 2007, the disclosures of which is incorporated herein by reference.
FIELD OF THE DISCLOSURE
[0002] The disclosure relates generally to materials that comprised metal organic frameworks. The disclosure also relates to materials that are useful to deliver molecules in a biological system as well as biological sensors.
BACKGROUND
[0003] Existing metal organic frameworks are toxic and lack biocompatibility .
SUMMARY
[0004] The disclosure provides porous biocompatible metal organic frameworks (bMOFs) developed from non-toxic starting materials. Such bMOF materials can be utilized in drug storage and delivery, flavoring and drying agents in food, catalysis, tissue engineering, dietary supplements, separation technology and gas storage.
[0005] The disclosure provides routes for the design and synthesis of 1, 2 and 3D-biologically useful bMOFs. The 3D- bMOFs of the disclosure are porous and capable of storing, within the pores of the framework, drugs; absorbing biomolecules; being used as a framework for tissue engineering and scaffolds; expansion within the gastrointestinal tract to serve as a dietary supplement; and the like.
[0006] The materials described in the disclosure can be tailored as 2D- or 3D- networks depending upon the metal ions, organic linkers and reaction conditions. With selection of the organic linkers, which represents an
integral part of the framework, and reaction conditions such as temperature, pH, solvent systems, reactant ratio and reaction time, the desired framework can be achieved. [0007] The disclosure provides a biocompatible metal- organic framework (bMOF) comprising: a plurality of biocompatible metallic cores, each core linked to at least one other core; a plurality of biocompatible linking ligands that connects adjacent cores, and a plurality of pores, wherein the plurality of linked cores defines the pore. In one aspect, the plurality of cores are different. In one aspect. At least two of the cores are different. In another aspect, the plurality of linking ligands are different. In yet another aspect, the porous framework is functionalized to bind an analyte or guest species. In yet another embodiment, the pores may be heterogeneous or homogenous in size. [0008] The disclosure also provides a biocompatible/environmentally friendly metal-organic framework comprising: a plurality of metal clusters, each metal cluster comprising one or more metal ions; and a plurality of non toxic charged multidentate linking ligands that connect adjacent metal clusters. In one embodiment, the the linking ligandcomprises an alkyl or cycloalkyl group, consisting of 1 to 20 carbon atoms, an aryl group, consisting of 1 to 5 phenyl rings, or an alkyl or aryl amine, consisting of alkyl or cycloalkyl groups having from 1 to 20 carbon atoms or aryl groups consisting of 1 to 5 phenyl rings, and in which multidentate functional groups are covalently bound to the substructure of the ligand. Multidentate functionality can be obtained using a member selected from the group consisting of CO2H, CS2H, NO2, SO3H, Si(OH)3, Ge(OH)3, Sn(OH)3, Si(SH)4, Ge(SH)4, Sn(SH)4, PO3H, AsO3H, AsO4H, P(SH)3, As(SH)3, CH(RSH)2, C(RSH)3, CH (RNH2) 2, C (RNH2) 3, CH(ROH)2, C(ROH)3, CH(RCN)2, C(RCN)3, wherein R is an alkyl group having from 1 to 5 carbon atoms, or an aryl group consisting of 1 to 2
phenyl rings; and, CH(SH)2, C(SH)3, CH (NH2) 2, C (NH2) 3, CH(OH)2, C(OH)3, CH(CN)2, and C(CN)3. In one embodiment, the linking moiety/ligand comprise carboxylic acid functional groups. This disclosure further includes cycloalkyl or aryl substructure that comprise from 1 to 5 rings that include either all carbon or a mixture of carbon, with nitrogen, oxygen, sulfur, boron, phosphorous, silicon and aluminum atoms making up the ring.
[0009] In one aspect, each ligand of the plurality of multidentate linking ligands includes two or more carboxylates . In another aspect, the metal ions are selected from the group consisting of Li+, Na+, Rb+, Mg2+, Ca2+, Sr2+, Ba2+, Sc3+, Ti4+, Zr4+, Ta3+, Cr3+, Mo3+, W3+, Mn3+, Fe3+, Fe2+, Ru3+, Ru2+, Os3+, Os2+, Co3+, Co2+, Ni2+, Ni+, Pd2+, Pd+, Pt2+, Pt+, Cu2+, Cu+, Au+, Zn2+, Al3+, Ga3+, In3+, Si4+, Si2+, Ge4+, Ge2+, Sn4+, Sn2+, Bi5+, Bi3+, and combinations thereof. In yet a further aspect, the multidentate linking ligand has 6 or more atoms (e.g., twelve or more atoms) that are incorporated in aromatic rings or non-aromatic rings. The one or more multidentate linking ligands can comprise anions of parent compounds selected from the group consisting of citric acid, malic acid, tartaric acid, retinoic acid, pantothenic acid, folic acid, nicitinic acid, oxalic acid, butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, myristoleic acid, palmitoleic acid, oleic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid, and docosahexaenoic acid. [0010] The disclosure provides a framework comprising a plurality of metal clusters comprising a metal ion and a linking ligand having a general structure selected from the group consisting of:
wherein M is a non-toxic metal and R is selected from the group consisting of -H, -OH, -ORl, aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo, wherein Rl can be -H, and aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo.
II
wherein M is a non-toxic metal and wherein n is 0, 1, or 2.
IV wherein M is a non-toxic metal;
V wherein M is a non-toxic metal;
VI wherein M is a non-toxic metal;
[0011] The bMOFs of the disclosure can further comprise a guest species; the guest species can increase the surface area of the MOF. In one aspect, the guest species is a biological agent (e.g., a protein, polypeptide, peptide, lipid, nucleic acid or small molecule agent) . In one aspect, the biological agent is a therapeutic agent or a diagnostic agent .
[0012] The disclosure also provides a dietary supplement comprising a bMOF of the disclosure. Such bMOFs are biocompatible and can be used for delivery of a drug or other biological agent or adsorption of a biological agent within the gastrointestinal tract. In another embodiment, the bMOF may be rendered expandable by absorption of a guest species within the gastrointestinal tract or made such that the framework is biodegradable during a desired time period there by, for example, giving the stimulus of being satiated. [0013] The disclosure provides a drug delivery composition comprising a bMOF having within its pores a drug, wherein the drug is delivered to the intestinal tract (e.g., an enteric coating) .
[0014] In yet another aspect, a food additive comprising a bMOF of the disclosure is provided.
[0015] The disclosure also provides a gas storage device comprising a MOF of the disclosure.
DESCRIPTION OF DRAWINGS [0016] Figure 1 shows characterization of a MOF of the disclosure .
[0017] Figure 2 shows characterization of a MOF of the disclosure .
[0018] Figure 3A-B shows a bMOF structure (MgBDCl) of the disclosure. (A) Binuclear cluster in MgBDC-I including Magnesium; Oxygen; and Carbon atoms. (B) 3D view of MgBDC-I. [0019] Figure 4A-B shows a bMOF structure (MgDHBDC-I) of the disclosure (A) Hexanuclear cluster in MgDHBDC-I including Magnesium; Oxygen; and Carbon atoms. (B) 3D view of MgDHBDC- 1.
[0020] Figure 5 shows an MgOBA-I structure of the disclosure including Magnesium; Oxygen; and Carbon atoms. [0021] Figure 6A-B shows a bMOF structure of the disclosure (MgBTC-I) . (A) shows a binuclear cluster of MgBTC-I including Magnesium; Oxygen; and Carbon. (B) shows Trigonal links are represented as dark triangles, while light gray triangles represent inorganic SBUs. Empty spaces are illustrated as spheres.
[0022] Figure 7 shows a bMOF (MgBTB-I) framework of the disclosure. An Octahedral Inorganic SBUs and tritopic links form 2D layer structure.
[0023] Figure 8A-B shows a bMOF structure of the disclosure (MgBTB-2) . (A) Fundamental building units of MgBTB-2 including Magnesium; Oxygen; Carbon; and Nitrogen. (B) Trigonal links are represented as triangles, while cubes represent inorganic SBUs. Empty spaces are illustrated as spheres .
[0024] Figure 9A-B shows a bMOF of the disclosure (MgBTB- 3) . (A) Fundamental building units of MgBTB-3 including Magnesium; Oxygen; Carbon; and Nitrogen. (B) Inorganic SBUs are represented as squares. Empty spaces are illustrated as spheres .
[0025] Figure 10 shows a bMOF of the disclosure (MgBTB-4). The structure consists of two types of inorganic SBUs (light and dark triangles and octahedra) and trigonal links. Empty spaces are illustrated as spheres.
[0026] Figure 11A-B shows yet another bMOF of the disclosure (MgBBC-I) . Trinuclear cluster of MgBBC-I including Magnesium; Oxygen; and Carbon. (B) shows a space fill model of the 2D structure.
DETAILED DESCRIPTION
[0027] As used herein and in the appended claims, the singular forms "a," "and," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a framework" includes a plurality of such frameworks and reference to "the composition" includes reference to one or more compositions, and so forth. [0028] Also, the use of "or" means "and/or" unless stated otherwise. Similarly, "comprise," "comprises," "comprising" "include," "includes," and "including" are interchangeable and not intended to be limiting.
[0029] It is to be further understood that where descriptions of various embodiments use the term "comprising," those skilled in the art would understand that in some specific instances, an embodiment can be alternatively described using language "consisting essentially of" or "consisting of."
[0030] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice of the disclosed methods and compositions, the exemplary methods, devices and materials are described herein.
[0031] Any publications discussed above and throughout the text are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior disclosure .
[0032] The use of MOFs comprising using non-toxic components as a drug storage and delivery material has not been reported nor the synthesis of biologically non-toxic MOFs. An advantage of the MOFs of the disclosure compared to previous MOFs is the non-toxic nature of the composition. In addition, the MOFs are highly stable with or without the presence of a guest molecule within the pores of the framework.
[0033] As used herein, a "cluster" refers to a repeating unit or units found in a framework. Such a framework can comprise a homogenous repeating cluster or a heterogeneous repeating cluster structure. A cluster comprises a transition metal and a linking moiety (sometimes referred to as a linking ligand) . A plurality of clusters linked together defines a framework.
[0034] A "linking moiety" refers to a mono-dentate, bidentate or multidentate compound that bind a biocompatible metal or a plurality of biocompatible metals, respectively. As used herein "linking ligand" or "linking moiety" refers to a chemical species (including neutral molecules and ions) that coordinate two or more metals and the definition of void regions or channels in the framework that is produced. The linking ligand of the disclosure is a non-toxic molecule. Examples of a linking ligand useful in the methods and compositions of the disclosure include citric acid, malic acid, and tartaric acid. Other linking moieties or ligands include, for example, methanoic acid, ethanoic acid, propanoic acid, butanoic acid, valeric acid, caproic acid,
caprylic acid, capric acid, lauric acid, mylistic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, cyclohexanecarboxylic acid, phenylacetic acid, benzoic acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, maleic acid, fumaric acid, phthalic acid, isophthalic acid, terephthalic acid, hemimellitic acid, trimellitic acid, trimesic acid, succinic anhydride, maleic anhydride, phthalic anhydride, glycolic acid, lactic acid, hydroxybutyric acid, mandelic acid, glyceric acid, malic acid, tartaric acid, citric acid, and ascorbic acid.
[0035] A linking moiety/ligand can comprise an alkyl or cycloalkyl group, consisting of 1 to 20 carbon atoms, an aryl group, consisting of 1 to 5 phenyl rings, or an alkyl or aryl amine, consisting of alkyl or cycloalkyl groups having from I to 20 carbon atoms or aryl groups consisting of 1 to 5 phenyl rings, and in which multidentate functional groups are covalently bound to the substructure of the ligand. Multidentate functionality can be selected from the group consisting of CO2H, CS2H, NO2, SO3H, Si(OH)3, Ge(OH)3, Sn(OH)3, Si(SH)4, Ge(SH)4, Sn(SH)4, PO3H, AsO3H, AsO4H, P(SH)3, As(SH)3, CH(RSH)2, C(RSH)3, CH (RNH2) 2, C (RNH2) 3, CH(ROH)2, C(ROH)3, CH(RCN)2, C(RCN)3, wherein R is an alkyl group having from 1 to 5 carbon atoms, or an aryl group consisting of 1 to 2 phenyl rings; and, CH(SH)2, C(SH)3, CH (NH2) 2, C (NH2) 3, CH(OH)2, C(OH)3, CH(CN)2, and C(CN)3. In one embodiment, the linking moiety/ligand comprise carboxylic acid functional groups. This disclosure further includes cycloalkyl or aryl substructure that comprise from 1 to 5 rings that include either all carbon or a mixture of carbon, with nitrogen, oxygen, sulfur, boron, phosphorous, silicon and aluminum atoms making up the ring.
[0036] Another aspect of this disclosure proivides that crystalline metal-organic microporous materials can be
synthesized by the addition of a solution of a metal salt to a solution containing an appropriate blend of ligands, some of which contain multidentate functional groups, as described herein, and others of which contain monodentate functional groups, in the presence of a suitable templating agent. [0037] In one aspect, the linking ligand comprises one or more carboxylates . For example, the linking ligand may be a polycarboxylic acid. As used herein, the term "polycarboxylic acid" indicates a dicarboxylic, tricarboxylic, tetracarboxylic, pentacarboxylic, and like monomeric polycarboxylic acids, and anhydrides, and combinations thereof, as well as polymeric polycarboxylic acids, anhydrides, copolymers, and combinations thereof. [0038] Illustratively, a monomeric polycarboxylic acid may be a dicarboxylic acid, including, but not limited to, unsaturated aliphatic dicarboxylic acids, saturated aliphatic dicarboxylic acids, aromatic dicarboxylic acids, unsaturated cyclic dicarboxylic acids, saturated cyclic dicarboxylic acids, hydroxy-substituted derivatives thereof, and the like. Or, illustratively, the polycarboxylic acid(s) itself may be a tricarboxylic acid, including, but not limited to, unsaturated aliphatic tricarboxylic acids, saturated aliphatic tricarboxylic acids, aromatic tricarboxylic acids, unsaturated cyclic tricarboxylic acids, saturated cyclic tricarboxylic acids, hydroxy-substituted derivatives thereof, and the like. It is appreciated that any such polycarboxylic acids may be optionally substituted, such as with hydroxy, halo, alkyl, alkoxy, and the like. In one variation, the polycarboxylic acid is the saturated aliphatic tricarboxylic acid, citric acid. Other suitable polycarboxylic acids are contemplated to include, but are not limited to, aconitic acid, adipic acid, azelaic acid, butane tetracarboxylic acid dihydride, butane tricarboxylic acid, chlorendic acid, citraconic acid, dicyclopentadiene-maleic acid adducts,
diethylenetriamine pentaacetic acid, adducts of dipentene and maleic acid, ethylenediamine tetraacetic acid (EDTA) , fully maleated rosin, maleated tall-oil fatty acids, fumaric acid, glutaric acid, isophthalic acid, itaconic acid, maleated rosin oxidized with potassium peroxide to alcohol then carboxylic acid, maleic acid, malic acid, mesaconic acid, biphenol A or bisphenol F reacted to introduce 3-4 carboxyl groups, oxalic acid, phthalic acid, sebacic acid, succinic acid, tartaric acid, terephthalic acid, tetrabromophthalic acid, tetrachlorophthalic acid, tetrahydrophthalic acid, trimellitic acid, trimesic acid, and the like, and anhydrides, and combinations thereof.
[0039] The disclosure provides a cluster comprising a metal ion and a linking ligand having a general structure selected from the group consisting of:
I wherein M is a non-toxic metal and R is selected from the group consisting of -H, -OH, -ORl, aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo, wherein Rl can be -H, and aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo.
II wherein M is a non-toxic metal and wherein n is 0, 1, or 2
III wherein M is a non-toxic metal;
IV wherein M is a non-toxic metal;
V wherein M is a non-toxic metal;
VII wherein M is a non-toxic metal; and
VIII wherein M is a non-toxic metal.
[0040] General formulas I-VIII above, depict a cluster comprising a metal ion and a linking moiety, however it will be recognized that the linking moieties can be modified or derivatized. For example, the linking moiety as set forth in Formula II can be modified as follows:
IX wherein each of Rl-15 are independently selected from the group consisting of -H, -OH, -OR16, aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo, wherein R16 can be -H, and aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo.
[0041] The term "alkyl" refers to a saturated monovalent chain of carbon atoms, which may be optionally branched; the term "cycloalkyl" refers to a monovalent chain of carbon atoms, a portion of which forms a ring; the term "alkenyl" refers to an unsaturated monovalent chain of carbon atoms including at least one double bond, which may be optionally branched; the term "cycloalkenyl" refers to an unsaturated monovalent chain of carbon atoms, a portion of which forms a ring; the term "heterocyclyl" refers to a monovalent chain of carbon and heteroatoms, wherein the heteroatoms are selected from nitrogen, oxygen, and sulfur, a portion of which, including at least one heteroatom, form a ring; the term "aryl" refers to an aromatic mono or polycyclic ring of carbon atoms, such as phenyl, naphthyl, and the like; and the term "heteroaryl" refers to an aromatic mono or polycyclic ring of carbon atoms and at least one heteroatom selected from nitrogen, oxygen, and sulfur, such as pyridinyl, pyrimidinyl, indolyl, benzoxazolyl, and the like. It is to be understood that each of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and heterocyclyl may be optionally substituted with independently selected groups such as alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, carboxylic acid and derivatives thereof, including esters, amides, and nitriles, hydroxy, alkoxy, acyloxy, amino, alkyl and dialkylamino, acylamino, thio, and the like, and combinations thereof. It is further to be understood that each of aryl and heteroaryl may be
optionally substituted with one or more independently selected substituents, such as halo, hydroxy, amino, alkyl or dialkylamino, alkoxy, alkylsulfonyl, cyano, nitro, and the like.
[0042] The disclosure also provides a biocompatible metal- organic framework (bMOF) comprising a homogenous or heterogeneous plurality of clusters, wherein the clusters form a framework.
[0043] A "framework," as used herein, refers to a framework of repeating clusters having a 2-D or 3-D structure .
[0044] A non-toxic chemical species refers to a chemical that when contacted with a biological organism does not have, or has limited, direct effect on cell apoptosis or death. Such materials can also be referred to as biologically safe, biologically inert, and biocompatible. [0045] As used herein "non-linking ligand" means a chemical species that is coordinated to a metal but does not act as a linker.
[0046] As used herein "guest" means any chemical species that resides within the void regions of an open framework solid that is not considered integral to the framework. Examples include: molecules of the solvent that fill the void regions during the synthetic process, other molecules that are exchanged for the solvent such as during immersion (via diffusion) or after evacuation of the solvent molecules, such as gases in a sorption experiment. A guest species may be a drug, therapeutic agent or diagnostic agent to be "carried" by the framework of the disclosure. A chemical species is used herein to include peptides, polypeptides, nucleic acid molecules, and fatty acids. Typically a drug will comprise a small organic molecule capable of filling or partially filling a void of a framework.
[0047] In yet another embodiment, the framework can be used as a scaffold for tissue engineering, wherein the framework may be infiltrate by cells or extracellular matrix material (e.g., collagen, elastin and the like) such that it support cell growth. Because the framework is biocompatible cells can grow and proliferate on the framework. [0048] As used herein "charge-balancing species" means a charged guest species that balances the charge of the framework. Quite often this species is strongly bound to the framework, i.e. via hydrogen bonds. It may decompose upon evacuation to leave a smaller charged species, or be exchanged for an equivalently charged species, but typically it cannot be removed from the pore of a metal-organic framework without collapse.
[0049] As used herein "space-filling agent" means a guest species that fills the void regions of an open framework during synthesis. Materials that exhibit permanent porosity remain intact after removal of the space-filling agent via heating and/or evacuation. Examples include: solvent molecules or molecular charge-balancing species. The latter may decompose upon heating, such that their gaseous products are easily evacuated and a smaller charge-balancing species remain in the pore (i.e. protons) . Sometimes space filling agents are referred to as templating agents .
[0050] As used herein "accessible metal site" means a site in a metal cluster and, in particular, a position adjacent to a metal in a metal cluster available for a chemical moiety such as a ligand to attach.
[0051] As used herein "open metal site" means a site in a metal cluster and, in particular, a position adjacent to a metal in a metal cluster from which a ligand or other chemical moiety has been removed, rendering that metal cluster reactive for adsorption of a chemical species having
available electron density for attachment to the metal cluster and, in particular, a metal in the metal cluster. [0052] As used herein "metal cluster" means any metal containing moiety present in a bMOF of the disclosure. This definition embracing single metal atoms or metal ions to groups of metals or metal ions that optionally include ligands or covalently bonded groups.
[0053] In one embodiment of the disclosure, a vehicle for delivery of a biological agent to an organism comprising a bMOF is provided. The bMOF of the embodiment includes a plurality of metal clusters and a plurality of charged multidentate non-toxic linking ligands that connect adjacent metal clusters. Each metal cluster includes one or more metal ions and at least one open metal site. Advantageously, the bMOF includes one or more sites for capturing/binding molecule to be delivered to an organism (e.g., a mammal, including a human) . In this embodiment, the one or more sites include the at least one open metal site. Biological agents that may be captured/stored in the frameworks of the disclosure include any biological molecules capable of fitting within a pore and comprising available electron density for attachment to the one or more sites. Such electron density includes molecules having multiple bonds between two atoms contained therein or molecules having a lone pair of electrons.
[0054] In a variation of this embodiment, the open metal site is formed by activating a precursor metal-organic framework. In a refinement, this activation involves removing one or more chemical moieties from the metal cluster. Typically, such moieties are ligands complexed to or bonded to a metal or metal ion within the metal clusters. Moreover, such moieties include species such as water, solvent molecules contained within the metal clusters, and other chemical moieties having electron density available for
attachment to the metal cluster and/or metal atoms or ions contained therein. Such electron density includes molecules having multiple bonds between two atoms contained therein or molecules having a lone pair of electrons. [0055] In another embodiment of the disclosure, a biocompatible metal organic framework is provided, the biocompatible metal organic framework comprises a plurality of metal cores and a plurality of charged non-toxic multidentate linking ligands that connect adjacent metal clusters. Each metal core includes one or more metal ions and at least one accessible metal site. The metal ions are typically alkali earth metals and the ligands are biocompatible acids. Advantageously, the metal-organic framework includes one or more sites for binding or storing a biological molecule or gas. In this embodiment, the one or more sites include the at least one accessible metal site. Gases that may be stored in the gas storage material of the disclosure include gas molecules comprising available electron density for attachment to the one or more sites for storing gas. Suitable examples of such gases include, but are not limited to, the gases comprising a component selected from the group consisting of ammonia, argon, carbon dioxide, carbon monoxide, hydrogen, and combinations thereof. In one variation of this embodiment, the accessible metal site is an open metal site.
[0056] The metal-organic frameworks used in the embodiments of the disclosure include a plurality of pores for adsorption of a biological molecule or gas. In one variation, the plurality of pores has a unimodal size distribution. In another variation, the plurality of pores have a multimodal (e.g., bimodal) size distribution. [0057] In another variation of the embodiments of the materials set forth above, the metal organic frameworks include metal clusters comprising one or more metal ions. In
another variation, the metal-organic frameworks include metal clusters that comprise two or more metal ions. In still another variation, the metal-organic frameworks include metal cores that comprise three or more metal ions. The metal ions can be selected from the group consisting of Li+, Na+, Rb+, Mg2+, Ca2+, Sr2+, Ba2+, Sc3+, Ti4+, Zr4+, Ta3+, Cr3+, Mo3+, W3+, Mn3+, Fe3+, Fe2+, Ru3+, Ru2+, Os3+, Os2+, Co3+, Co2+, Ni2+, Ni+, Pd2+, Pd+, Pt2+, Pt+, Cu2+, Cu+, Au+, Zn2+, Al3+, Ga3+, In3+, Si4+, Si2+, Ge4+, Ge2+, Sn4+, Sn2+, Bi5+, Bi3+, and combinations thereof .
[0058] An environmentally friendly metal-organic framework of the disclosure comprises a plurality of metal cores, each metal core comprising one or more metal ions; and a plurality of non toxic charged multidentate linking ligands that connect adjacent metal cores. In one aspect, the each ligand of the plurality of multidentate linking ligands includes two or more carboxylates . In yet another aspect, the multidentate linking ligand has twelve or more atoms that are incorporated in aromatic rings or non-aromatic rings. In a further aspect, the one or more multidentate linking ligands comprise anions of parent compounds selected from the group consisting of citric acid, malic acid, tartaric acid, retinoic acid, pantothenic acid, folic acid, nicitinic acid, oxalic acid, butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, myristoleic acid, palmitoleic acid, oleic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid, and docosahexaenoic acid.
[0059] The metal-organic framework used in the disclosure optionally further comprises a non-linking ligand. In a variation, the non-linking ligand is selected from the group consisting of 02~, sulfate, nitrate, nitrite, sulfite, bisulfite, phosphate, hydrogen phosphate, dihydrogen
phosphate, diphosphate, triphosphate, phosphite, chloride, chlorate, bromide, bromate, iodide, iodate, carbonate, bicarbonate, sulfide, hydrogen sulphate, selenide, selenate, hydrogen selenate, telluride, tellurate, hydrogen tellurate, nitride, phosphide, arsenide, arsenate, hydrogen arsenate, dihydrogen arsenate, antimonide, antimonate, hydrogen antimonate, dihydrogen antimonate, fluoride, boride, borate, hydrogen borate, perchlorate, chlorite, hypochlorite, perbromate, bromite, hypobromite, periodate, iodite, hypoiodite; and combinations thereof.
[0060] The metal-organic frameworks of the disclosure optionally further comprise space-filling agents, adsorbed chemical species, guest species, and combinations thereof. In some variations of the disclosure, space-filling agents, adsorbed chemical species and guest species increase the surface area of the metal-organic framework. Suitable spacefilling agents include, for example, a component selected from the group consisting of:
(i) alkyl amines and their corresponding alkyl ammonium salts, containing linear, branched, or cyclic aliphatic groups, having from 1 to 20 carbon atoms;
(ii) aryl amines and their corresponding aryl ammonium salts having from 1 to 5 phenyl rings;
(iii) alkyl phosphonium salts, containing linear, branched, or cyclic aliphatic groups, having from 1 to 20 carbon atoms;
(iv) aryl phosphonium salts, having from 1 to 5 phenyl rings;
(v) alkyl organic acids and their corresponding salts, containing linear, branched, or cyclic aliphatic groups, having from 1 to 20 carbon atoms;
(vi) aryl organic acids and their corresponding salts, having from 1 to 5 phenyl rings;
(vii) aliphatic alcohols, containing linear, branched, or cyclic aliphatic groups, having from 1 to 20 carbon atoms;
(viii) aryl alcohols having from 1 to 5 phenyl rings;
(a) inorganic anions from the group consisting of sulfate, nitrate, nitrite, sulfite, bisulfite, phosphate, hydrogen phosphate, dihydrogen phosphate, diphosphate, triphosphate, phosphite, chloride, chlorate, bromide, bromate, iodide, iodate, carbonate, bicarbonate, O. sup.2-, diphosphate, sulfide, hydrogen sulphate, selenide, selenate, hydrogen selenate, telluride, tellurate, hydrogen tellurate, nitride, phosphide, arsenide, arsenate, hydrogen arsenate, dihydrogen arsenate, antimonide, antimonate, hydrogen antimonate, dihydrogen antimonate, fluoride, boride, borate, hydrogen borate, perchlorate, chlorite, hypochlorite, perbromate, bromite, hypobromite, periodate, iodite, hypoiodite, and the corresponding acids and salts of said inorganic anions;
(b) ammonia, carbon dioxide, methane, oxygen, argon, nitrogen, ethylene, hexane, benzene, toluene, xylene, chlorobenzene, nitrobenzene, naphthalene, thiophene, pyridine, acetone, 1 , 2-dichloroethane, methylenechloride, tetrahydrofuran, ethanolamine, triethylamine, trifluoromethylsulfonic acid, N,N-dimethyl formamide, N, N- diethyl formamide, dimethylsulfoxide, chloroform, bromoform, dibromomethane, iodoform, diiodomethane, halogenated organic solvents, N, N-dimethylacetamide, N, N-diethylacetamide, 1- methyl-2-pyrrolidinone, amide solvents, methylpyridine, dimethylpyridine, diethylethe, and mixtures thereof. Examples of adsorbed chemical species include ammonia, carbon dioxide, carbon monoxide, hydrogen, amines, methane, oxygen, argon, nitrogen, argon, organic dyes, polycyclic organic molecules, flavorants, small molecule therapeutics and diagnostics and combinations thereof. Examples of guest species are organic
molecules with a molecular weight less than about 100 g/mol, organic molecules with a molecular weight less than about 300 g/mol, organic molecules with a molecular weight less than about 600 g/mol, organic molecules with a molecular weight greater than about 600 g/mol. In some variations, adsorbed chemical species, guest species, and space-filling agents are introduced in the metal-organic frameworks by contacting the metal-organic frameworks with a pre-selected chemical species, guest species, or space-filling agent. In another variation of the disclosure, the metal organic framework comprises an interpenetrating metal-organic framework that increases the surface area of the metal-organic framework. [0061] In still another embodiment of the disclosure, a method of forming the material set forth above is provided. The metal-organic framework is formed by combining a solution comprising a solvent and metal ions selected from the group consisting of Li+, Na+, Rb+, Mg2+, Ca2+, Sr2+, Ba2+, Sc3+, Ti4+, Zr4+, Ta3+, Cr3+, Mo3+, W3+, Mn3+, Fe3+, Fe2+, Ru3+, Ru2+, Os3+, Os2+, Co3+, Co2+, Ni2+, Ni+, Pd2+, Pd+, Pt2+, Pt+, Cu2+, Cu+, Au+, Zn2+, Al3+, Ga3+, In3+, Si4+, Si2+, Ge4+, Ge2+, Sn4+, Sn2+, Bi5+, Bi3+, and combinations thereof with a multidentate linking ligand to form a percursor bMOF. The multidentate linking ligand can comprise two or more carboxylates or anions of parent compounds selected from the group consisting of citric acid, malic acid, tartaric acid, retinoic acid, pantothenic acid, folic acid, nicitinic acid, oxalic acid, butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, myristoleic acid, palmitoleic acid, oleic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid, and docosahexaenoic acid. [0062] The bMOFs of the disclosure can be formed by using any of Schemes I or II.
Scheme I wherein M is a nontoxic metal cation. In this embodiment, the linking moiety is shown as being a terephthalic acid or derivative thereof. Using the method of scheme I, a framework as set forth in Formula X, can be generated:
X
Scheme II wherein M is a nontoxic metal cation. In this embodiment, the linking moiety is shown as being a trimesic acid or a derivative thereof (n is 1, 2 or 3) .
[0063] The metal-organic framework used in the disclosure optionally further comprises a non-linking ligand. In a variation, the non-linking ligand is selected from the group
consisting of O2 , sulfate, nitrate, nitrite, sulfite, bisulfite, phosphate, hydrogen phosphate, dihydrogen phosphate, diphosphate, triphosphate, phosphite, chloride, chlorate, bromide, bromate, iodide, iodate, carbonate, bicarbonate, sulfide, hydrogen sulphate, selenide, selenate, hydrogen selenate, telluride, tellurate, hydrogen tellurate, nitride, phosphide, arsenide, arsenate, hydrogen arsenate, dihydrogen arsenate, antimonide, antimonate, hydrogen antimonate, dihydrogen antimonate, fluoride, boride, borate, hydrogen borate, perchlorate, chlorite, hypochlorite, perbromate, bromite, hypobromite, periodate, iodite, hypoiodite; and combinations thereof
[0064] In one variation of the disclosure, the one or more ligands are removed by heating the precursor MOF. Typically, in this variation, the precursor MOF is heated to a temperature from about 30 0C to about 300 0C. In another variation, the one or more ligands are removed by exposing the precursor MOF to a vacuum. Typically, the vacuum is characterized by having a pressure less than 10~3 torr. In other variations, from about 10~5 torr to about 700 torr. In still another variation of the disclosure, the one or more ligands are removed by simultaneously heating the precursor MOF and by exposing the precursor MOF to a vacuum. In still another variation, the solution used in the method of the disclosure may also include space-filling agents. Examples of suitable space-filling agents are set forth above. In a refinement of each of these variations, one or more ligands of the precursor MOF may be exchanged with another ligand or ligands that are more easily removed by subsequent heating and/or exposure to a vacuum.
[0065] In another aspect, the framework set forth above may include an interpenetrating framework that increases the surface area of the framework. Although the frameworks of the disclosure may advantageously exclude such interpenetration,
there are circumstances when the inclusion of an interpenetrating framework may be used to increase the surface area.
[0066] The frameworks of the disclosure can be used as sorption devices in vitro or in vivo. Sorption is a general term that refers to a process resulting in the association of atoms or molecules with a target material. Sorption includes both adsorption and absorption. Absorption refers to a process in which atoms or molecules move into the bulk of a porous material, such as the absorption of water by a sponge. Adsorption refers to a process in which atoms or molecules move from a bulk phase (that is, solid, liquid, or gas) onto a solid or liquid surface. The term adsorption may be used in the context of solid surfaces in contact with liquids and gases. Molecules that have been adsorbed onto solid surfaces are referred to generically as adsorbates, and the surface to which they are adsorbed as the substrate or adsorbent. Adsorption is usually described through isotherms, that is, functions which connect the amount of adsorbate on the adsorbent, with its pressure (if gas) or concentration (if liquid) . In general, desorption refers to the reverse of adsorption, and is a process in which molecules adsorbed on a surface are transferred back into a bulk phase. [0067] The following non-limiting examples illustrate the various embodiments of the disclosure. Those skilled in the art will recognize many variations that are within the spirit of the disclosure and scope of the claims.
EXAMPLES
[0068] One (1 ) -dimensional, 2D- and 3D- environmentally friendly metal organic frameworks (efMOFs or bMOFs) of the disclosure have been synthesized and characterized by PXRD, X-ray signal crystal determinations and TGA. For example,
the following synthetic routes can be used to generate certain species of the compositions of the disclosure:
(a) Synthesis of lD-efMOF:
H0" OH o
(b) Synthesis of 2D-efMOF:
(c) Synthesis of 3D-efMOF:
(CϊfiC AcKi)
[0069] Figure 1 shows the characterization of Mg3 (citrate) 2 (H2O) 6 -8H2O and Ca(MaI) -2H2O. Figure 2 shows the characterization of Ca3 (citrate) 2 (H2O) 2 -8H2O and Ca (Tar) (H2O) 2 -2H2O.
[0070] MgBDC-I. A solid mixture of terephthalic acid (H2BDC, 240 mg) and magnesium nitrate hexahydrate Mg (NO3) 2* 6H2O (128 mg) was dissolved in N, N-diethylformamide (13 mL) and 2.0 M aqueous HNO3 solution (40 μL) in a 20-mL vial. 60 μL diisopropylamine and 2 mL DEF was mixed in a 4-mL vial. The 4-mL vial was placed in the 20-mL vial to allow diffusion. The 20-mL vial was capped and placed in an
isothermal oven at 85 0C for 72 h. Figure 3 shows a framework of MgBDC-I .
[0071] MgDHBDC-I. A solid mixture of 2,5- dihydroxyterephthalic acid (H2DHBDC, 40 mg) and magnesium nitrate hexahydrate Mg (NO3) 2 * 6H2O (150 mg) was dissolved in a mixture of N, N-diethylformamide (8 mL) , distilled water (1 mL) and 2.0 M aqueous HNO3 solution (20 μL) in a 20-mL vial. 20 μL diisopropylamine and 2 mL N, N-diethylformamide was mixed in a 4-mL vial. The 4-mL vial was placed in the 20-mL vial to allow diffusion. The 20-mL vial was capped and placed in an isothermal oven at 65 0C for 60 days. Figure 4 shows a framework of MgDHBD-I.
[0072] MgOBA-I. A solid mixture of 4 , 4 ' -oxybis (benzoic acid) (H2OBA, 50.0 mg) and magnesium nitrate hexahydrate Mg (NO3) 2' 6H2O (10.0 mg) was dissolved in N, N-dimthylformamide (5 mL) in a 20-mL vial. 20 μL diisopropylamine and 2 mL N, N- dimthylformamide was mixed in a 4-mL vial. The 4-mL vial was placed in the 20-mL vial to allow diffusion. The 20-mL vial was capped and placed in an isothermal oven at 65 0C for 10 days. Figure 5 shows a framework of MgOBA-I.
[0073] MgBTC-I. A solid mixture of trimesic acid (H3BTC, 50.0 mg) and magnesium nitrate hexahydrate Mg (NO3) 2 • 6H2O (150.0 mg) was dissolved in a mixture of N, N- diethylformamide (5 mL) , ethanol (3 mL) and 2-ethyl-l-hexanol (2 mL) in a 20-mL vial. The vial was capped and placed in an isothermal oven at 85 0C for 3 days. Figure 6 shows a framework of MgBTC-I .
[0074] MgBTB-I. A solid mixture of 1, 3, 5-tri (4 ' -carboxy- 4 , 4 ' -biphenyl) benzene (H3BTB, 43.5 mg) and magnesium acetate tetrahydrate Mg (OAc) 2 • 4H2O (5.0 mg) was dissolved in a mixture of N, N-dimethylacetatmide (3 mL) and dimethylamine (20 μL) in a 4-mL vial. The vial was capped and placed in an isothermal oven at 120 0C for 3 days. Figure 7 shows a framework of MgBTB-I .
[0075] MgBTB-2. A solid mixture of 4, 4' , 4" -benzene-1, 3, 5- triyl-tri-benzoic acid (H3BTB, 10.0 mg) and magnesium nitrate hexahydrate Mg (NO3) 2 * 6H2O (6.0 mg) was dissolved in a mixture of N, N-diethylformamide (2.5 mL) and distilled water (0.50 mL) in a 4-mL vial. The vial was capped and placed in an isothermal oven at 100 0C for 7 days. Figure 8 shows a framework of MgBTB-2.
[0076] MgBTB-3. A solid mixture of 4, 4' , 4" -benzene-1, 3, 5- triyl-tri-benzoic acid (H3BTB, 10.0 mg) and magnesium acetate tetrahydrate Mg (OAc) 2 * 4H2O (5.0 mg) was dissolved in a mixture of N-methylpyrrolidone (2 mL) and distilled water (1 mL) in a 20-mL vial. 20 μL triethylamine and 2 mL N-methylpyrrolidone was mixed in a 4-mL vial. The 4-mL vial was placed in the 20- mL vial to allow diffusion. The 20-mL vial was capped and placed in an isothermal oven at 65 0C for 7 days. Figure 9 shows a framework of MgBTB-3.
[0077] MgBTB-4. A solid mixture of 4, 4' , 4" -benzene-1, 3, 5- triyl-tri-benzoic acid (H3BTB, 30.0 mg) and magnesium acetate tetrahydrate Mg (OAc) 2 * 4H2O (40.0 mg) was dissolved in a mixture of N, N-diethylformamide (10 mL) and 2.0 M aqueous HNO3 solution (120 μL) in a 20-mL vial. 10 μL N, N- diisopropylamine and 2 mL N, N-diethylformamide was mixed in a 4-mL vial. The 4-mL vial was placed in the 20-mL vial to allow diffusion. The 20-mL vial was capped and placed in an isothermal oven at 65 0C for 7 days. Figure 10 shows a framework of MgBTB-5.
[0078] MgBBC-I. A solid mixture of 4, 4' , 4" -benzene-1, 3, 5- triyl-tri-biphenylcarboxylic acid (H3BBC, 30.0 mg) and magnesium nitrate hexahydrate Mg (NO3) 2 • 6H2O (4.0 mg) was dissolved in a mixture of N, N-diethylformamide (1.5 mL) , distilled water (0.30 mL) and 2M aqueous HNO3 solution (20 μL) in a 4-mL vial. The vial was capped and placed in an isothermal oven at 100 0C for 5 days. Figure 11 shows a framework of MgBBC-I .
Table A: Summary of Magnesium based edible MOF structures
[0079] Although a number of embodiments and features have been described above, it will be understood by those skilled in the art that modifications and variations of the described embodiments and features may be made without departing from the teachings of the disclosure or the scope of the disclosure as defined by the appended claims.
Claims
1. A biocompatible metal-organic framework (bMOF) comprising : a plurality of biocompatible metallic cores, each core linked to at least one other core; a plurality of biocompatible linking ligands that connects adjacent cores, and a plurality of pores, wherein the plurality of linked cores defines the pore.
2. The bMOF of claim 1, wherein the plurality of cores are heterogeneous .
3. The bMOF of claim 1 or 2, wherein the plurality of linking ligands are heterogeneous.
4. An environmentally friendly metal-organic framework (bMOF) comprising: a plurality of metal cores, each metal core comprising one or more metal ions; and a plurality of non toxic charged multidentate linking ligands that connect adjacent metal clusters.
5. The environmentally friendly metal-organic framework of claim 4, wherein each ligand of the plurality of multidentate linking ligands includes two or more carboxylates .
6. The environmentally friendly metal-organic framework of claim 4, wherein the metal ions are selected from the group consisting of Li+, Na+, Rb+, Mg2+, Ca2+, Sr2+, Ba2+, Sc3+, Ti4+, Zr4+, Ta3+, Cr3+, Mo3+, W3+, Mn3+, Fe3+, Fe2+, Ru3+, Ru2+, Os3+, Os2+, Co3+, Co2+, Ni2+, Ni+, Pd2+, Pd+, Pt2+, Pt+, Cu2+, Cu+, Au+, Zn2+, Al3+, Ga3+, In3+, Si4+, Si2+, Ge4+, Ge2+, Sn4+, Sn2+, Bi5+, Bi3+, and combinations thereof.
7. The environmentally friendly metal-organic framework of claim 4, wherein the multidentate linking ligand has twelve or more atoms that are incorporated in aromatic rings or non- aromatic rings.
8. The environmentally friendly metal-organic framework of claim 4, wherein the one or more multidentate linking ligands comprise anions of parent compounds selected from the group consisting of citric acid, malic acid, tartaric acid, retinoic acid, pantothenic acid, folic acid, nicitinic acid, oxalic acid, butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, myristoleic acid, palmitoleic acid, oleic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid, and docosahexaenoic acid.
9. The bMOF of claim 1 or 4 further comprising a guest species .
10. The bMOF of claim 9, wherein the guest species increase the surface area of the bMOF.
11. The bMOF of claim 9, wherein the guest species is biological agent.
12. The bMOF of claim 11, wherein the biological agent is a protein, lipid, nucleic acid or small molecule agent.
13. The bMOF of claim 11 or 12, wherein the biological agent is a therapeutic agent.
14. The bMOF of claim 11 or 12, wherein the biological agent is a diagnostic agent.
15. The bMOF of claim 1 or 4, further comprising interpenetrating bMOFs that increases the surface area of the metal-organic framework.
16. The bMOF of claim 1 or 4, further comprising an adsorbed chemical species .
17. The bMOF of claim 16, wherein the adsorbed chemical species is selected from the group consisting of ammonia, carbon dioxide, carbon monoxide, hydrogen, amines, methane, oxygen, argon, nitrogen, argon, organic dyes, polycyclic organic molecules, and combinations thereof.
18. A dietary supplement comprising a bMOF of claim 1 or 4.
19. A drug delivery agent comprising the bMOF of claim 1 or 4.
20. A gas storage device comprising a bMOF of claim 1 or 4.
21. A method of making an environmentally friendly metal organic framework, comprising: reacting a plurality of metal clusters, each metal cluster comprising one or more metal ions with one or more non toxic charged multidentate linking ligands that connect adjacent metal clusters.
22. A porous framework material comprising a plurality of biocompatible metallic cores, each core linked to at least one other core; a plurality of biocompatible linking ligands that connects adjacent cores, wherein the linking ligand comprises at least two carboxylates, and a plurality of pores, wherein the plurality of linked cores defines a pore and a biological molecules chemically attached to a surface of pores of the porous framework.
23. The porous framework material of claim 22, wherein the linking ligand is selected from the group consisting of citric acid, malic acid, and tartaric acid.
24. The porous framework material of claim 22, wherein the linking ligand comprises a member selected from the group consisting of methanoic acid, ethanoic acid, propanoic acid, butanoic acid, valeric acid, caproic acid, caprylic acid, capric acid, lauric acid, mylistic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, cyclohexanecarboxylic acid, phenylacetic acid, benzoic acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, maleic acid, fumaric acid, phthalic acid, isophthalic acid, terephthalic acid, hemimellitic acid, trimellitic acid, trimesic acid, succinic anhydride, maleic anhydride, phthalic anhydride, glycolic acid, lactic acid, hydroxybutyric acid, mandelic acid, glyceric acid, malic acid, tartaric acid, citric acid, and ascorbic acid.
25. The porous framework material of claim 22, wherein the linking ligand comprises a member selected from the group consisting of Formic acid, Acetic acid, Propionic acid, Butyric acid, Valeric acid, Caproic acid, Enanthic acid, Caprylic acid, Pelargonic acid, Capric acid, Lauric acid, Palmitic acid, Stearic acid, Docosahexaenoic acid, Eicosapentaenoic acid, Keto acids, Pyruvic acid, Acetoacetic acid, Benzoic acid, and Salicylic acid.
26. The porous framework material of claim 22, wherein the linking ligand is selected from the group consisting of Aldaric acid, Oxalic acid, Malonic acid, Malic acid, Succinic acid, Glutaric acid, Adipic acid, Tricarboxylic acids, Isocitric acid, Aconitic acid, and Propane-1, 2, 3- tricarboxylic acid (tricarballylic acid, carballylic acid) .
27. The porous framework material of claim 22, wherein the frame work comprises repeating units having a general formula :
I wherein M is a non-toxic metal and R is selected from the group consisting of -H, -OH, -ORl, aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo, wherein Rl can be -H, and aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo.
28. The porous framework material of claim 22, wherein the framework comprises repeating units having a general formula:
II wherein M is a non-toxic metal and wherein n is 0, 1, or 2.
29. The porous framework material of claim 22, wherein the framework comprises repeating units having a general formula:
III wherein M is a non-toxic metal.
30. The porous framework material of claim 22, wherein the framework comprises repeating units having a general formula:
IV wherein M is a non-toxic metal.
31. The porous framework material of claim 22, wherein the framework comprises repeating units having a general formula:
V wherein M is a non-toxic metal.
32. The porous framework material of claim 22, wherein the framework comprises repeating units having a general formula:
VI wherein M is a non-toxic metal.
33. The porous framework material of claim 22, wherein the framework comprises repeating units having a general formula
VII wherein M is a non-toxic metal.
34. The porous framework material of claim 22, wherein the framework comprising repeating units having a general formula :
35. The porous framework material of claim 22, wherein the framework comprises a metaloxide.
36. The porous framework material of claim 22, wherein the biocompatible linking ligand comprises an alkyl or cycloalkyl group, consisting of 1 to 20 carbon atoms, an aryl group, consisting of 1 to 5 phenyl rings, or an alkyl or aryl amine, consisting of alkyl or cycloalkyl groups having from 1 to 20 carbon atoms or aryl groups consisting of 1 to 5 phenyl rings, and and wherein a multidentate functional group is covalently bound to the ligand.
37. The porous framework material of claim 36, wherien the multidentate functional group can be selected from the group consisting of CO2H, CS2H, NO2, SO3H, Si(OH)3, Ge(OH)3, Sn(OH)3, Si(SH)4, Ge(SH)4, Sn(SH)4, PO3H, AsO3H, AsO4H, P(SH)3, As(SH)3, CH(RSH)2, C(RSH)3, CH (RNH2) 2, C (RNH2) 3, CH(ROH)2, C(ROH)3, CH(RCN)2, C(RCN)3, wherein R is an alkyl group having from 1 to 5 carbon atoms, or an aryl group consisting of 1 to 2 phenyl rings; and, CH(SH)2, C(SH)3, CH (NH2) 2, C (NH2) 3, CH(OH)2, C(OH)3, CH(CN)2, and C(CN)3.
38. A dietary supplement comprising a porous framework material of any one of claims 22-37.
39. A method for delivery a drug to a subject comprising administering the porous framework of any one of claim 22-37 to a subject.
40. The method of claim 39, wherein the drug is a peptide, polypeptide, protein, nucleic acid, fatty acid or small molecule .
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/680,141 US8691748B2 (en) | 2007-09-25 | 2008-09-25 | Edible and biocompatible metal-organic frameworks |
EP08833035.2A EP2190662B1 (en) | 2007-09-25 | 2008-09-25 | Edible and biocompatible metal-organic frameworks |
ES08833035T ES2713194T3 (en) | 2007-09-25 | 2008-09-25 | Edible and biocompatible organometallic frameworks |
JP2010527153A JP5730574B2 (en) | 2007-09-25 | 2008-09-25 | Biocompatible metal-organic structure suitable for edible use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97508907P | 2007-09-25 | 2007-09-25 | |
US60/975,089 | 2007-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009042802A1 true WO2009042802A1 (en) | 2009-04-02 |
Family
ID=40511860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/077741 WO2009042802A1 (en) | 2007-09-25 | 2008-09-25 | Edible and biocompatible metal-organic frameworks |
Country Status (5)
Country | Link |
---|---|
US (1) | US8691748B2 (en) |
EP (1) | EP2190662B1 (en) |
JP (1) | JP5730574B2 (en) |
ES (1) | ES2713194T3 (en) |
WO (1) | WO2009042802A1 (en) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8480955B2 (en) | 2008-12-29 | 2013-07-09 | The Regents Of The University Of California | Gas sensor incorporating a porous framework |
US8480792B2 (en) | 2007-07-17 | 2013-07-09 | The Regents Of The University Of California | Preparation of functionalized zeolitic frameworks |
US8540802B2 (en) | 2007-05-11 | 2013-09-24 | The Regents Of The University Of California | Adsorptive gas separation of multi-component gases |
US8674128B2 (en) | 2009-01-15 | 2014-03-18 | The Regents Of The University Of California | Conductive organometallic framework |
US8691748B2 (en) | 2007-09-25 | 2014-04-08 | The Regents Of The University Of California | Edible and biocompatible metal-organic frameworks |
US8709134B2 (en) | 2009-02-02 | 2014-04-29 | The Regents Of The University Of California | Reversible ethylene oxide capture in porous frameworks |
US8742152B2 (en) | 2011-02-04 | 2014-06-03 | The Regents Of The University Of California | Preparation of metal-catecholate frameworks |
KR20140081818A (en) * | 2011-10-13 | 2014-07-01 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Metal-organic frameworks with exceptionally large pore aperatures |
US8841471B2 (en) | 2009-09-25 | 2014-09-23 | The Regents Of The University Of California | Open metal organic frameworks with exceptional surface area and high gas storage capacity |
US8852320B2 (en) | 2011-01-21 | 2014-10-07 | The Regents Of The University Of California | Preparation of metal-triazolate frameworks |
US8876953B2 (en) | 2009-06-19 | 2014-11-04 | The Regents Of The University Of California | Carbon dioxide capture and storage using open frameworks |
US8916722B2 (en) | 2009-06-19 | 2014-12-23 | The Regents Of The University Of California | Complex mixed ligand open framework materials |
US8946454B2 (en) | 2008-06-05 | 2015-02-03 | The Regents Of The University Of California | Chemical framework compositions and methods of use |
US9045387B2 (en) | 2009-07-27 | 2015-06-02 | The Regents Of The University Of California | Oxidative homo-coupling reactions of aryl boronic acids using a porous copper metal-organic framework as a highly efficient heterogeneous catalyst |
US9102609B2 (en) | 2010-07-20 | 2015-08-11 | The Regents Of The University Of California | Functionalization of organic molecules using metal-organic frameworks (MOFS) as catalysts |
CN104865232A (en) * | 2015-05-26 | 2015-08-26 | 天津师范大学 | Method for selectively detecting ascorbic acid by utilizing metal-organic framework material |
WO2015161037A1 (en) * | 2014-04-16 | 2015-10-22 | The Regents Of The University Of California | Very low density metal organic frameworks with large pore volumes |
WO2015142944A3 (en) * | 2014-03-18 | 2015-11-19 | The Regents Of The University Of California | Mesoscopic materials comprised of ordered superlattices of microporous metal-organic frameworks |
US9269473B2 (en) | 2010-09-27 | 2016-02-23 | The Regents Of The University Of California | Conductive open frameworks |
US9512145B2 (en) | 2008-12-18 | 2016-12-06 | The Regents Of The University Of California | Porous reactive framework |
KR101683150B1 (en) * | 2016-07-21 | 2016-12-06 | 주식회사 나예코스메틱 | Method of manufacturing calcium citrate with high degree of electrolytic dissociation |
CN106588951A (en) * | 2017-01-23 | 2017-04-26 | 辽宁大学 | Zinc-based porous metal organic framework compound as well as preparation method and application thereof |
CN106673992A (en) * | 2015-11-11 | 2017-05-17 | 中国科学院大连化学物理研究所 | Bimetal organic framework material as well as preparation and application thereof |
US10087205B2 (en) | 2014-03-28 | 2018-10-02 | The Regents Of The University Of California | Metal organic frameworks comprising a plurality of SBUS with different metal ions and/or a plurality of organic linking ligands with different functional groups |
CN109054808A (en) * | 2018-08-29 | 2018-12-21 | 陕西师范大学 | Magnesium with fluorescence sense ability-aromatic carboxylic acids porous coordination and its preparation method and application |
CN109265702A (en) * | 2018-11-01 | 2019-01-25 | 广东工业大学 | A kind of sulfonic acid funtionalized zirconium-based metallic organic framework material, preparation method and its application |
US10287304B2 (en) | 2014-02-19 | 2019-05-14 | The Regents Of The University Of California | Acid, solvent, and thermal resistant metal-organic frameworks |
US10821417B2 (en) | 2015-11-27 | 2020-11-03 | The Regents Of The University Of California | Zeolitic imidazolate frameworks |
WO2021103232A1 (en) * | 2019-11-25 | 2021-06-03 | 上海纳米技术及应用国家工程研究中心有限公司 | Preparation method for core-shell nanoparticles based on lipid membrane and metal organic framework |
CN112979982A (en) * | 2021-02-25 | 2021-06-18 | 西南交通大学 | Organic frame material with anti-inflammatory function and preparation method thereof |
CN116284809A (en) * | 2022-12-26 | 2023-06-23 | 西安工程大学 | Metal-organic framework material based on V-type asymmetric pentacarboxylic acid ligand, preparation method and application |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008091976A1 (en) * | 2007-01-24 | 2008-07-31 | The Regents Of The University Of California | Crystalline 3d- and 2d-covalent organic frameworks |
JP5305279B2 (en) * | 2007-10-12 | 2013-10-02 | Jx日鉱日石エネルギー株式会社 | Porous metal complex and method for producing the same |
EP2279157B1 (en) * | 2008-03-17 | 2012-01-25 | Basf Se | Use of formiate-based porous organometallic framework materials for storing methane |
CN102414255B (en) * | 2009-02-27 | 2015-09-23 | 环球油品公司 | Block coordination copolymers |
US8425662B2 (en) | 2010-04-02 | 2013-04-23 | Battelle Memorial Institute | Methods for associating or dissociating guest materials with a metal organic framework, systems for associating or dissociating guest materials within a series of metal organic frameworks, and gas separation assemblies |
EP2729180B1 (en) | 2011-07-08 | 2019-01-23 | The University of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
JPWO2013069721A1 (en) * | 2011-11-08 | 2015-04-02 | 株式会社クラレ | Metal complex, adsorbent, occlusion material and separation material comprising the same |
JPWO2013084826A1 (en) * | 2011-12-07 | 2015-04-27 | 株式会社クラレ | Metal complex, adsorbent, occlusion material and separation material comprising the same |
US9987583B2 (en) | 2013-11-22 | 2018-06-05 | The Regents Of The University Of California | Polymers functionalized with brønsted acid groups |
WO2016010525A1 (en) * | 2014-07-15 | 2016-01-21 | Halliburton Energy Services, Inc. | Metal-organic frameworks as porous proppants |
US10206871B2 (en) | 2014-10-14 | 2019-02-19 | The University Of Chicago | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof |
US10806694B2 (en) | 2014-10-14 | 2020-10-20 | The University Of Chicago | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof |
JP6609964B2 (en) * | 2015-03-31 | 2019-11-27 | 東ソー株式会社 | Porous coordination polymer |
JP6519948B2 (en) * | 2015-06-03 | 2019-05-29 | 株式会社豊田中央研究所 | Tris (carboxyanthracenylphenyl) benzene, crystalline network complex using the same and gas storage material |
KR101776169B1 (en) | 2015-09-25 | 2017-09-08 | 한국화학연구원 | Organic-inorganic hybrid nanoporous materials comprising three kinds of metal, and use thereof |
US11246877B2 (en) | 2016-05-20 | 2022-02-15 | The University Of Chicago | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof |
CN106053413B (en) * | 2016-06-13 | 2019-01-18 | 华东师范大学 | A kind of metal organic fluorescence methanol sense film and preparation method thereof |
US11767225B2 (en) | 2016-08-10 | 2023-09-26 | Research Triangle Institute | Solid-state crystallization of metal organic frameworks within mesoporous materials methods and hybrid materials thereof |
CN106810570B (en) * | 2016-12-16 | 2019-01-18 | 商丘师范学院 | Green light type terbium (III) complex based on trans-aconitic acid ligand and preparation method thereof |
JP6638685B2 (en) * | 2017-03-31 | 2020-01-29 | トヨタ自動車株式会社 | Metal organic structure and manufacturing method thereof |
KR101890588B1 (en) | 2017-04-24 | 2018-09-28 | 숙명여자대학교산학협력단 | Imaging-agents loaded nanocrystalline metal-organic frameworks for containing and method for preparing the same |
JP7066750B2 (en) * | 2017-06-01 | 2022-05-13 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア | L-calcium lactate structure as a naturally degradable carrier |
EP3638367A4 (en) | 2017-08-02 | 2021-07-21 | The University of Chicago | Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof |
CN111094228B (en) * | 2017-08-22 | 2024-02-09 | 积水化学工业株式会社 | Composition, method for producing molded article, and molded article |
JP7049595B2 (en) * | 2017-12-21 | 2022-04-07 | 株式会社豊田中央研究所 | Aluminum organic structures, adsorption materials using them, and methods for manufacturing them. |
CN111769294B (en) * | 2019-04-02 | 2021-11-23 | 中车工业研究院有限公司 | Preparation method of MOF compound and non-noble metal catalyst |
AU2020263512A1 (en) * | 2019-04-26 | 2021-10-07 | Exxonmobil Research And Engineering Company | Mixed-metal mixed-organic framework systems for selective CO2 capture |
CN114206823A (en) * | 2019-06-25 | 2022-03-18 | 学校法人立教学院 | Hydrogen storage materials comprising metal organic structures |
CN110289407A (en) * | 2019-06-26 | 2019-09-27 | 浙江大学 | A kind of carbon coating cobalt-doping zinc oxide nano material for lithium ion battery |
KR20210068806A (en) * | 2019-12-02 | 2021-06-10 | 한국화학연구원 | Dehumidifier having nanoporous hybrid material and dehumidification system for electronics thereof |
KR20210068805A (en) * | 2019-12-02 | 2021-06-10 | 한국화학연구원 | Dehumidifier having nanoporous hybrid material and dehumidification system thereof |
CN112778122B (en) * | 2021-01-15 | 2022-11-22 | 佛山科学技术学院 | Preparation method and application of indium-based metal organic framework material |
WO2024020357A1 (en) * | 2022-07-18 | 2024-01-25 | The Regents Of The University Of California | Hydrocarbon oxidation with dioxygen in iron-containing metal-organic frameworks |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040225134A1 (en) * | 2003-05-09 | 2004-11-11 | The Regents Of The University Of Michigan | Implementation of a strategy for achieving extraordinary levels of surface area and porosity in crystals |
US20050154222A1 (en) * | 2004-01-13 | 2005-07-14 | Basf Aktiengesellschaft | Process for preparing an organometallic framework material |
US20060154807A1 (en) * | 2004-10-22 | 2006-07-13 | Yaghi Omar M | Covalently linked organic frameworks and polyhedra |
US20060185388A1 (en) * | 2005-02-23 | 2006-08-24 | Basf Aktiengesellschaft | Metal-organic framework materials for gaseous hydrocarbon storage |
US20060252641A1 (en) | 2005-04-07 | 2006-11-09 | Yaghi Omar M | High gas adsorption in a microporous metal-organic framework with open-metal sites |
WO2006125761A2 (en) | 2005-05-24 | 2006-11-30 | Basf Aktiengesellschaft | Method for producing porous metal-organic framework materials |
US20070068389A1 (en) * | 2005-09-26 | 2007-03-29 | Yaghi Omar M | Metal-organic frameworks with exceptionally high capacity for storage of carbon dioxide at room-temperature |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4532225A (en) * | 1983-02-11 | 1985-07-30 | Mobil Oil Corporation | Preparation of metal-containing zeolite catalysts of increased stability and activity |
US5160500A (en) * | 1985-10-21 | 1992-11-03 | Mobil Oil Corporation | Zeolite synthesis using an alcohol or like molecules |
EP0318099A3 (en) * | 1987-11-25 | 1989-11-15 | Union Carbide Corporation | Monoalkylene glycol production using mixed metal framework compositions |
US5208335A (en) * | 1991-03-19 | 1993-05-04 | Air Products And Chemicals, Inc. | Reversible oxygen sorbent compositions |
JP3574185B2 (en) * | 1994-09-02 | 2004-10-06 | 小松屋化学株式会社 | Anhydrotrimagnesium citrate and its preparation |
US5648508A (en) * | 1995-11-22 | 1997-07-15 | Nalco Chemical Company | Crystalline metal-organic microporous materials |
BR0016665A (en) * | 1999-12-23 | 2002-09-03 | Unilever Nv | Bleaching composition, and, bleaching and preparation methods of a bleaching composition |
US6501000B1 (en) * | 2000-04-04 | 2002-12-31 | Exxonmobil Research And Engineering Company | Late transition metal catalyst complexes and oligomers therefrom |
EP1383775B1 (en) * | 2001-04-30 | 2006-08-02 | The Regents of The University of Michigan | Isoreticular metal-organic frameworks, process for forming the same, and systematic design of pore size and functionality therein,with application for gas storage |
US20030078311A1 (en) * | 2001-10-19 | 2003-04-24 | Ulrich Muller | Process for the alkoxylation of organic compounds in the presence of novel framework materials |
US6929679B2 (en) * | 2002-02-01 | 2005-08-16 | Basf Aktiengesellschaft | Method of storing, uptaking, releasing of gases by novel framework materials |
US6624318B1 (en) * | 2002-05-30 | 2003-09-23 | Basf Aktiengesellschaft | Process for the epoxidation of an organic compound with oxygen or an oxygen-delivering compounds using catalysts containing metal-organic frame-work materials |
US6893564B2 (en) * | 2002-05-30 | 2005-05-17 | Basf Aktiengesellschaft | Shaped bodies containing metal-organic frameworks |
US6617467B1 (en) * | 2002-10-25 | 2003-09-09 | Basf Aktiengesellschaft | Process for producing polyalkylene carbonates |
US7008607B2 (en) * | 2002-10-25 | 2006-03-07 | Basf Aktiengesellschaft | Process for preparing hydrogen peroxide from the elements |
US7357836B2 (en) * | 2003-03-06 | 2008-04-15 | University Of Massachusetts | Crystalline membranes |
US7309380B2 (en) * | 2003-06-30 | 2007-12-18 | Basf Aktiengesellschaft | Gas storage system |
US20050004404A1 (en) * | 2003-07-03 | 2005-01-06 | Basf Akiengesellschaft | Process for the alkoxylation of monools in the presence of metallo-organic framework materials |
JP2007518707A (en) * | 2003-12-05 | 2007-07-12 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Metal organic polyhedron |
CN1930107B (en) * | 2004-03-05 | 2011-07-27 | 协和化学工业株式会社 | Particles of aluminum salt hydroxide containing organic acid anion, method for production thereof and use thereof |
US7524444B2 (en) * | 2004-11-09 | 2009-04-28 | Basf Aktiengesellschaft | Shaped bodies containing metal-organic frameworks |
DE102004061238A1 (en) | 2004-12-20 | 2006-06-22 | Basf Ag | Method for the enrichment of methane in methane containing gas mixtures comprises contacting the gas mixture with at least a sorbent containing a porous metal-organic structure material |
DE102005000938A1 (en) | 2005-01-07 | 2006-07-20 | Basf Ag | Adsorptive recovery of xenon from krypton-xenon mixed gas |
EP1877412A4 (en) * | 2005-04-22 | 2011-05-04 | Univ South Florida | Zeolite-like metal organic frameworks (zmofs): modular approach to the synthesis of organic-inorganic hybrid porous materials having a zeolite like topology |
US7763767B2 (en) * | 2005-05-04 | 2010-07-27 | Exxonmobil Chemicals Patents Inc. | Adsorption process with on-line adsorbent removal |
DE102005039623A1 (en) * | 2005-08-22 | 2007-03-01 | Basf Ag | Process for the preparation of organometallic frameworks Main groups containing metal ions |
DE102005054523A1 (en) | 2005-11-14 | 2007-05-16 | Basf Ag | Porous organometallic framework containing another polymer |
ZA200805557B (en) | 2005-12-21 | 2009-12-30 | Uop Llc | The use of mofs in pressure swing adsorption |
PL1988996T3 (en) | 2006-02-28 | 2018-01-31 | Univ Michigan Regents | Preparation of functionalized zeolitic frameworks |
WO2007118843A1 (en) * | 2006-04-18 | 2007-10-25 | Basf Se | Metal oxides produced from metal-organic framework materials |
EP2010315A2 (en) * | 2006-04-18 | 2009-01-07 | Basf Se | Organometallic aluminum fumarate backbone material |
US20070248575A1 (en) * | 2006-04-19 | 2007-10-25 | Jerome Connor | Bone graft composition |
WO2008091976A1 (en) | 2007-01-24 | 2008-07-31 | The Regents Of The University Of California | Crystalline 3d- and 2d-covalent organic frameworks |
US7687432B2 (en) * | 2007-02-02 | 2010-03-30 | Miami University | Mesh-adjustable molecular sieve |
WO2008140788A1 (en) | 2007-05-11 | 2008-11-20 | The Regents Of The University Of California | Adsorptive gas separation of multi-component gases |
TW200914115A (en) | 2007-05-14 | 2009-04-01 | Shell Int Research | Process for producing purified natural gas from natural gas comprising water and carbon dioxide |
EP2167511A4 (en) * | 2007-07-17 | 2010-12-22 | Univ California | Preparation of functionalized zeolitic frameworks |
EP2190662B1 (en) | 2007-09-25 | 2018-12-26 | The Regents of The University of California | Edible and biocompatible metal-organic frameworks |
US8946454B2 (en) * | 2008-06-05 | 2015-02-03 | The Regents Of The University Of California | Chemical framework compositions and methods of use |
US20110277767A1 (en) | 2008-12-18 | 2011-11-17 | The Regents Of The University Of California | Metal organic frameworks (mofs) for air purification |
WO2010080618A2 (en) | 2008-12-18 | 2010-07-15 | The Regents Of The University Of California | Porous reactive frameworks |
US8480955B2 (en) | 2008-12-29 | 2013-07-09 | The Regents Of The University Of California | Gas sensor incorporating a porous framework |
EP2382043A1 (en) | 2009-01-15 | 2011-11-02 | The Regents of the University of California | Conductive organometallic framework |
EP2384237A1 (en) | 2009-02-02 | 2011-11-09 | The Regents of The University of California | Reversible ethylene oxide capture in porous frameworks |
JP5698229B2 (en) | 2009-06-19 | 2015-04-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | Complex mixed ligand open skeleton materials |
KR20120096454A (en) | 2009-06-19 | 2012-08-30 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Organo-metallic frameworks and methods of making same |
EP2437867A4 (en) | 2009-06-19 | 2012-12-05 | Univ California | Carbon dioxide capture and storage using open frameworks |
KR20120084662A (en) | 2009-07-27 | 2012-07-30 | 바스프 에스이 | Oxidative homo-coupling reactions of aryl boronic acids using a porous copper metal-organic framework as a highly efficient heterogeneous catalyst |
US8841471B2 (en) | 2009-09-25 | 2014-09-23 | The Regents Of The University Of California | Open metal organic frameworks with exceptional surface area and high gas storage capacity |
US8524932B2 (en) * | 2010-09-30 | 2013-09-03 | Basf Se | Process for preparing porous metal-organic frameworks based on aluminum fumarate |
-
2008
- 2008-09-25 EP EP08833035.2A patent/EP2190662B1/en active Active
- 2008-09-25 JP JP2010527153A patent/JP5730574B2/en active Active
- 2008-09-25 US US12/680,141 patent/US8691748B2/en active Active
- 2008-09-25 ES ES08833035T patent/ES2713194T3/en active Active
- 2008-09-25 WO PCT/US2008/077741 patent/WO2009042802A1/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040225134A1 (en) * | 2003-05-09 | 2004-11-11 | The Regents Of The University Of Michigan | Implementation of a strategy for achieving extraordinary levels of surface area and porosity in crystals |
US20050154222A1 (en) * | 2004-01-13 | 2005-07-14 | Basf Aktiengesellschaft | Process for preparing an organometallic framework material |
US20060154807A1 (en) * | 2004-10-22 | 2006-07-13 | Yaghi Omar M | Covalently linked organic frameworks and polyhedra |
US20060185388A1 (en) * | 2005-02-23 | 2006-08-24 | Basf Aktiengesellschaft | Metal-organic framework materials for gaseous hydrocarbon storage |
US20060252641A1 (en) | 2005-04-07 | 2006-11-09 | Yaghi Omar M | High gas adsorption in a microporous metal-organic framework with open-metal sites |
WO2006125761A2 (en) | 2005-05-24 | 2006-11-30 | Basf Aktiengesellschaft | Method for producing porous metal-organic framework materials |
US20070068389A1 (en) * | 2005-09-26 | 2007-03-29 | Yaghi Omar M | Metal-organic frameworks with exceptionally high capacity for storage of carbon dioxide at room-temperature |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8540802B2 (en) | 2007-05-11 | 2013-09-24 | The Regents Of The University Of California | Adsorptive gas separation of multi-component gases |
US8480792B2 (en) | 2007-07-17 | 2013-07-09 | The Regents Of The University Of California | Preparation of functionalized zeolitic frameworks |
US8691748B2 (en) | 2007-09-25 | 2014-04-08 | The Regents Of The University Of California | Edible and biocompatible metal-organic frameworks |
US8946454B2 (en) | 2008-06-05 | 2015-02-03 | The Regents Of The University Of California | Chemical framework compositions and methods of use |
US9512145B2 (en) | 2008-12-18 | 2016-12-06 | The Regents Of The University Of California | Porous reactive framework |
US8735161B2 (en) | 2008-12-29 | 2014-05-27 | The Regents Of The University Of California | Gas sensor incorporating a porous framework |
US8480955B2 (en) | 2008-12-29 | 2013-07-09 | The Regents Of The University Of California | Gas sensor incorporating a porous framework |
US8674128B2 (en) | 2009-01-15 | 2014-03-18 | The Regents Of The University Of California | Conductive organometallic framework |
US8709134B2 (en) | 2009-02-02 | 2014-04-29 | The Regents Of The University Of California | Reversible ethylene oxide capture in porous frameworks |
US8876953B2 (en) | 2009-06-19 | 2014-11-04 | The Regents Of The University Of California | Carbon dioxide capture and storage using open frameworks |
US8916722B2 (en) | 2009-06-19 | 2014-12-23 | The Regents Of The University Of California | Complex mixed ligand open framework materials |
US9045387B2 (en) | 2009-07-27 | 2015-06-02 | The Regents Of The University Of California | Oxidative homo-coupling reactions of aryl boronic acids using a porous copper metal-organic framework as a highly efficient heterogeneous catalyst |
US8841471B2 (en) | 2009-09-25 | 2014-09-23 | The Regents Of The University Of California | Open metal organic frameworks with exceptional surface area and high gas storage capacity |
US9102609B2 (en) | 2010-07-20 | 2015-08-11 | The Regents Of The University Of California | Functionalization of organic molecules using metal-organic frameworks (MOFS) as catalysts |
US9269473B2 (en) | 2010-09-27 | 2016-02-23 | The Regents Of The University Of California | Conductive open frameworks |
US9978474B2 (en) | 2010-09-27 | 2018-05-22 | The Regents Of The University Of California | Conductive open frameworks |
US8852320B2 (en) | 2011-01-21 | 2014-10-07 | The Regents Of The University Of California | Preparation of metal-triazolate frameworks |
US8742152B2 (en) | 2011-02-04 | 2014-06-03 | The Regents Of The University Of California | Preparation of metal-catecholate frameworks |
US9078922B2 (en) | 2011-10-13 | 2015-07-14 | The Regents Of The University Of California | Metal-organic frameworks with exceptionally large pore aperatures |
KR20140081818A (en) * | 2011-10-13 | 2014-07-01 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Metal-organic frameworks with exceptionally large pore aperatures |
KR102011160B1 (en) | 2011-10-13 | 2019-08-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Metal-organic frameworks with exceptionally large pore aperatures |
US9669098B2 (en) | 2011-10-13 | 2017-06-06 | The Regents Of The University Of California | Metal-organic frameworks with exceptionally large pore aperatures |
WO2013112212A3 (en) * | 2011-10-13 | 2014-10-09 | The Regents Of The University Of California | Metal-organic frameworks with exceptionally large pore aperatures |
US10287304B2 (en) | 2014-02-19 | 2019-05-14 | The Regents Of The University Of California | Acid, solvent, and thermal resistant metal-organic frameworks |
WO2015142944A3 (en) * | 2014-03-18 | 2015-11-19 | The Regents Of The University Of California | Mesoscopic materials comprised of ordered superlattices of microporous metal-organic frameworks |
US10494386B2 (en) | 2014-03-18 | 2019-12-03 | The Regents Of The University Of California | Mesoscopic materials comprised of ordered superlattices of microporous metal-organic frameworks |
CN107148422A (en) * | 2014-03-18 | 2017-09-08 | 加利福尼亚大学董事会 | The mesoscopic material of orderly superlattices comprising micropore metal organic backbone |
US10087205B2 (en) | 2014-03-28 | 2018-10-02 | The Regents Of The University Of California | Metal organic frameworks comprising a plurality of SBUS with different metal ions and/or a plurality of organic linking ligands with different functional groups |
WO2015161037A1 (en) * | 2014-04-16 | 2015-10-22 | The Regents Of The University Of California | Very low density metal organic frameworks with large pore volumes |
CN104865232A (en) * | 2015-05-26 | 2015-08-26 | 天津师范大学 | Method for selectively detecting ascorbic acid by utilizing metal-organic framework material |
CN106673992A (en) * | 2015-11-11 | 2017-05-17 | 中国科学院大连化学物理研究所 | Bimetal organic framework material as well as preparation and application thereof |
US10821417B2 (en) | 2015-11-27 | 2020-11-03 | The Regents Of The University Of California | Zeolitic imidazolate frameworks |
KR101683150B1 (en) * | 2016-07-21 | 2016-12-06 | 주식회사 나예코스메틱 | Method of manufacturing calcium citrate with high degree of electrolytic dissociation |
CN106588951B (en) * | 2017-01-23 | 2019-01-01 | 辽宁大学 | A kind of porous metal-organic framework compound and its preparation method and application based on zinc |
CN106588951A (en) * | 2017-01-23 | 2017-04-26 | 辽宁大学 | Zinc-based porous metal organic framework compound as well as preparation method and application thereof |
CN109054808A (en) * | 2018-08-29 | 2018-12-21 | 陕西师范大学 | Magnesium with fluorescence sense ability-aromatic carboxylic acids porous coordination and its preparation method and application |
CN109265702A (en) * | 2018-11-01 | 2019-01-25 | 广东工业大学 | A kind of sulfonic acid funtionalized zirconium-based metallic organic framework material, preparation method and its application |
WO2021103232A1 (en) * | 2019-11-25 | 2021-06-03 | 上海纳米技术及应用国家工程研究中心有限公司 | Preparation method for core-shell nanoparticles based on lipid membrane and metal organic framework |
CN112979982A (en) * | 2021-02-25 | 2021-06-18 | 西南交通大学 | Organic frame material with anti-inflammatory function and preparation method thereof |
CN116284809A (en) * | 2022-12-26 | 2023-06-23 | 西安工程大学 | Metal-organic framework material based on V-type asymmetric pentacarboxylic acid ligand, preparation method and application |
CN116284809B (en) * | 2022-12-26 | 2024-03-22 | 西安工程大学 | Metal-organic framework material based on V-type asymmetric pentacarboxylic acid ligand, preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
EP2190662B1 (en) | 2018-12-26 |
JP2011517309A (en) | 2011-06-02 |
US20100286022A1 (en) | 2010-11-11 |
EP2190662A4 (en) | 2012-09-05 |
US8691748B2 (en) | 2014-04-08 |
EP2190662A1 (en) | 2010-06-02 |
ES2713194T3 (en) | 2019-05-20 |
JP5730574B2 (en) | 2015-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2190662A1 (en) | Edible and biocompatible metal-organic frameworks | |
Griffin et al. | A periodic table of metal-organic frameworks | |
Gosselin et al. | Permanently microporous metal–organic polyhedra | |
CN111094304B (en) | Zirconium terephthalate-based metal-organic frameworks with open metal sites | |
Ayati et al. | Emerging adsorptive removal of azo dye by metal–organic frameworks | |
Schoedel et al. | The asc trinodal platform: two-step assembly of triangular, tetrahedral, and trigonal-prismatic molecular building blocks | |
Furukawa et al. | The chemistry and applications of metal-organic frameworks | |
Papaefstathiou et al. | Inverted metal–organic frameworks: solid-state hosts with modular functionality | |
Wang et al. | Three neutral metal–organic frameworks with micro-and meso-pores for adsorption and separation of dyes | |
Chen et al. | Temperature dependent selective gas sorption of the microporous metal-imidazolate framework [Cu (L)][H 2 L= 1, 4-di (1 H-imidazol-4-yl) benzene] | |
US7799120B2 (en) | Metal-organic frameworks with exceptionally high capacity for storage of carbon dioxide at room-temperature | |
Hulvey et al. | Enhanced H 2 adsorption enthalpy in the low-surface area, partially fluorinated coordination polymer Zn 5 (triazole) 6 (tetrafluoroterephthalate) 2 (H 2 O) 2· 4H 2 O | |
Dybtsev et al. | Pre-synthesized secondary building units in the rational synthesis of porous coordination polymers | |
Colwell et al. | Buffered coordination modulation as a means of controlling crystal morphology and molecular diffusion in an anisotropic metal–organic framework | |
Yaghi | Hydrogen storage in metal-organic frameworks | |
Hou et al. | Strategies for induced defects in metal–organic frameworks for enhancing adsorption and catalytic performance | |
Binaeian et al. | Enhancing toxic gas uptake performance of Zr-based MOF through uncoordinated carboxylate and copper insertion; ammonia adsorption | |
JP5044815B2 (en) | Method for producing metal complex | |
JP2014166971A (en) | Porous polymer metal complex, gas adsorbent, gas separation apparatus and gas storage apparatus using the same | |
Lv et al. | PH-modulated formation of uniform MOF-5 sheets | |
González et al. | CO2 capture by MOFs | |
JP6555861B2 (en) | Coordinating complex containing fluorine or salt thereof, gas adsorbent and production method thereof, gas separation device and gas storage device using the same | |
US20220372049A1 (en) | Multimetal-metal organic framework adsorbent | |
Pham et al. | Historical and contemporary perspectives on metal–organic frameworks for gas sensing applications: a review | |
Frem et al. | The amazing chemistry of metal-organic frameworks |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08833035 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008833035 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010527153 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12680141 Country of ref document: US |